var title_f3_18_3360="Dynamometry";
var content_f3_18_3360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dynamometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dynamometry is the most objective measurement of grip strength and forearm muscle integrity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3360=[""].join("\n");
var outline_f3_18_3360=null;
var title_f3_18_3361="Nadifloxacin: International drug information";
var content_f3_18_3361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nadifloxacin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acuatim (JP);",
"     </li>",
"     <li>",
"      Nadibact (IN);",
"     </li>",
"     <li>",
"      Nadiflox (IN);",
"     </li>",
"     <li>",
"      Nadixa (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4151911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4151912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acne vulgaris and bacterial skin infections",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4151914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to lesions twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4151915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, topical: 1%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10511 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3361=[""].join("\n");
var outline_f3_18_3361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302627\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4151911\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4151912\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4151914\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821128\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4151915\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10511|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3362="Osteochondritis dissecans of the knee";
var content_f3_18_3362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Plain radiograph showing osteochondritis dissecans of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteror-posterior radiograph of the right knee of a patient with an OCD lesion on the medial femoral condyle (A). The abnormality of the articular surface is difficult to visualize on this view. The tunnel view (B and C) clearly shows the lesion on the medial femoral condyle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robertson W, Kelly BT, Green DW. Osteochondritis dissecans of the knee in children. Curr Opin Pediatr 2003; 15:38. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3362=[""].join("\n");
var outline_f3_18_3362=null;
var title_f3_18_3363="STEP procedure";
var content_f3_18_3363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serial transverse enteroplasty procedure (STEP) for short bowel syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The small arrows show the direction of insertion of the GIA stapler and the sites of the mesenteric defects. The staplers are placed in the 90&deg; and 270&deg; orientations using the mesentery as the 0&deg; reference point.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kim HB, Fauza D, Garza J, et al. Serial transverse enteroplasty (STEP): a novel bowel lengthening procedure. J Pediatr Surg 2003; 38:425. Copyright &copy;2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3363=[""].join("\n");
var outline_f3_18_3363=null;
var title_f3_18_3364="Ioxaglate meglumine and ioxaglate sodium: Patient drug information";
var content_f3_18_3364=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ioxaglate meglumine and ioxaglate sodium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40194?source=see_link\">",
"     see \"Ioxaglate meglumine and ioxaglate sodium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hexabrix&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein or artery only.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ioxaglate meglumine, ioxaglate sodium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12070 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3364=[""].join("\n");
var outline_f3_18_3364=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184042\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025444\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025446\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025445\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025449\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025450\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025452\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025448\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025453\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025454\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40194?source=related_link\">",
"      Ioxaglate meglumine and ioxaglate sodium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3365="Deferiprone: Drug information";
var content_f3_18_3365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Deferiprone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/43/30388?source=see_link\">",
"    see \"Deferiprone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13301498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13688783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferriprox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13299487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Chelating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13301554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Round dose to the nearest 250 mg (or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet). If serum ferritin falls consistently below 500 mcg/L, consider temporary treatment interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Transfusional iron overload:",
"     </b>",
"     Oral: Initial: 25 mg/kg 3 times/day (75 mg/kg/day); individualize dose based on response and therapeutic goal; maximum dose: 33 mg/kg 3 times/day (99 mg/kg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13301555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Begin at the low end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13301558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments are provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13301557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments are provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13301556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-6em;margin-left:6em;\">",
"     ANC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : In addition to treatment interruption, consider hospitalization (and other clinically-appropriate management); do not resume or rechallenge unless the potential benefits outweigh potential risks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infection: Interrupt treatment; monitor ANC more frequently",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13307628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferriprox&reg;: 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14280404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM302558.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM302558.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13301559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the morning, at mid day and in the evening. Administration with food may decrease nausea.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13299489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of transfusional iron overload due to thalassemia syndromes with inadequate response to other chelation therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13299486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Deferiprone may be confused with deferoxamine, deferasirox",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13301519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Chromaturia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain/discomfort (10%), vomiting (10%), appetite increased (4%), diarrhea (3%), dyspepsia (2%), weight gain (2%), appetite decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (6% to 7%), agranulocytosis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (8%), AST increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular and skeletal: Arthralgia (10%), back pain (2%), limb pain (2%), arthropathy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome, anaphylactic shock, atrial fibrillation, bilirubin increased, bruxism, cardiac failure, cerebellar syndrome, cerebral hemorrhage, chills, chondropathy, CPK increased, cryptococcal cutaneous infection, dehydration, depression, diplopia, enterocolitis, enteroviral encephalitis, epistaxis, fever, furuncle, gait disturbance, gastric ulcer, glycosuria, hemoglobinuria, hemoptysis, Henoch-Sch&ouml;nlein purpura, hepatitis (infectious), hepatomegaly, hyperhydrosis, hyper-/hypotension, hypersensitivity, hypospadias, intracranial pressure increased, jaundice, metabolic acidosis, multiorgan failure, myositis, obsessive compulsive disorder, pancreatitis, pancytopenia, papilledema, parotid gland enlargement, periorbital edema, peripheral edema, pharyngitis, photosensitivity, pneumonia, pruritus, psychomotor skills impaired, pulmonary embolism, pustular rash, pyramidal tract syndrome, rash, rectal hemorrhage, retinal toxicity, seizure, sepsis, somnolence, subcutaneous abscess, thrombocytosis, torsade de pointes, trismus, urticaria, zinc levels decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13301503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to deferiprone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13301504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Agranulocytosis:",
"     <b>",
"      [U.S. Boxed Warning]: May cause agranulocytosis, which could lead to serious infections (some fatal). Agranulocytosis may be preceded by neutropenia; monitor absolute neutrophil count (ANC) prior to treatment initiation and weekly during therapy. If infection develops, interrupt treatment and monitor ANC more frequently. Patients should promptly report any symptoms which may indicate infection. Interrupt treatment if neutropenia (ANC &lt;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      ) develops;",
"     </b>",
"     withhold any other medications which may also be associated with neutropenia; monitor CBC, corrected WBC, ANC, and platelets daily until ANC recovery. If ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , consider hospitalization (and other clinically appropriate management); do not resume or rechallenge unless the potential benefits outweigh potential risks. Neutropenia and agranulocytosis were generally reversible upon discontinuation. The mechanism for deferiprone-induced agranulocytosis is not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Elevations in ALT values have been observed; monitor ALT and consider treatment interruption for persistent elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Zinc deficiency: Lower plasma zinc concentrations have been observed; monitor zinc levels and supplement if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolongation: Use with caution in patients at risk for QT prolongation (eg, bradycardia, cardiac hypertrophy, congestive HF, diuretic use, hypokalemia or hypomagnesemia). There has been a single case report of torsade de pointes in a patient with a history of QT prolongation, although a thorough QT study has not been conducted for deferiprone. Patients should promptly report any symptoms suggestive of arrhythmias (eg, dizziness, lightheadedness, palpitations, seizure. or syncope).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neutropenic agents:  Avoid concurrent use with other agents associated with neutropenia (or agranulocytosis); if concurrent use cannot be avoided, monitor ANC.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13301538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of UGT1A6, UGT1A9, UGT2B15, UGT2B7",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13320101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     UGT1A6 Inhibitors: May increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13301539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Deferiprone may bind with polyvalent cations (eg, aluminum, zinc). Allow at least 4 hours between other medications or supplements containing polyvalent cations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13301499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13301500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. Although there is limited data in humans, deferiprone may cause fetal harm if administered during pregnancy. During treatment with deferiprone in women of reproductive potential, pregnancy should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13301501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13301502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13307625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease nausea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ferriprox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $4098.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13307626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum ferritin (every 2-3 months); ANC (at baseline and weekly during treatment); if ANC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , monitor CBC, WBC (corrected for nucleated RBCs), ANC, and platelets daily until ANC recovery; ALT (monthly); zinc levels; symptoms suggestive of QT prolongation; signs or symptoms of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ferriprox (AR, AT, AU, BE, BR, CH, CL, CZ, DE, DK, EE, FI, FR, GB, GR, HK, ID, IE, IL, IT, NL, NO, NZ, PT, SE, SG, TH, TR);",
"     </li>",
"     <li>",
"      Kelfer (GR, IN, MY, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13301542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron-chelating agent with affinity for ferric ion (iron III); binds to ferric ion and forms a 3:1 (deferiprone:iron) complex which is excreted in the urine. Has a lower affinity for other metals such as copper, aluminum, and zinc.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13301545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 1.6 L/kg (in thalassemia patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily by UGT 1A6; major metabolite (3-O-glucuronide) lacks iron-binding capacity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half life elimination: 1.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (75% to 90%; as free deferiprone, the iron deferiprone complex, and glucuronide metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ceci A, Baiardi P, Felisi M, et al, &ldquo;The Safety and Effectiveness of Deferiprone in a Large-Scale, 3-Year Study in Italian patients,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2002, 118(1):330-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3365/abstract-text/12100170/pubmed\" id=\"12100170\" target=\"_blank\">",
"        12100170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen AR, Galanello R, Piga A, et al, Safety and Effectiveness of Long-Term Therapy With the Oral Iron Chelator Deferiprone,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 102(5):1583-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3365/abstract-text/12763939/pubmed\" id=\"12763939\" target=\"_blank\">",
"        12763939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neufeld EJ, &ldquo;Oral Chelators Deferasirox and Deferiprone for Transfusional Iron Overload in Thalassemia Major: New Data, New Questions,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(9):3436-41.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17092 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D2AB0E8FD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3365=[""].join("\n");
var outline_f3_18_3365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301498\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13688783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299487\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301554\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301555\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301558\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301557\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301556\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307628\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14280404\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301559\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299489\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299486\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301519\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301503\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301504\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301538\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13320101\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301539\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301499\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301500\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301501\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301502\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307625\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322919\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307626\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733212\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301542\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301545\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17092|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/43/30388?source=related_link\">",
"      Deferiprone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3366="Milrinone: Drug information";
var content_f3_18_3366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Milrinone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/22/20835?source=see_link\">",
"    see \"Milrinone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"    see \"Milrinone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Milrinone Lactate Injection;",
"     </li>",
"     <li>",
"      Primacor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase-3 Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      CHF/Hemodynamic support:",
"     </b>",
"     I.V.: Loading dose (optional; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     ): 50 mcg/kg administered over 10 minutes followed by a maintenance dose titrated according to hemodynamic and clinical response; Maintenance dose: I.V. infusion: 0.375-0.75 mcg/kg/minute; lower initial doses of 0.1 mcg/kg/minute (with final doses of 0.2-0.3 mcg/kg/minute) have also been recommended (Lindenfeld, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When initiating an infusion of 0.5 mcg/kg/minute without a loading dose, significant hemodynamic changes seen at 30 minutes with similar effects on pulmonary capillary wedge pressure and cardiac index seen at 2 and 3 hours, respectively, compared to loading dose regimen (Baruch, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Manufacturer recommended adjustment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.43 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.38 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.33 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20 mL/minute/ 1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.28 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.23 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.2 mcg/kg/minute",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Alternative Dosing Adjustments in Patients with Renal Impairment",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         (mL/min)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Starting dose (mcg/kg/min)",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.375",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.5",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.75",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         <sup>",
"          1",
"         </sup>",
"         Based on expert opinion",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.375",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.375",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0625",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Consider alternative therapy",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0625",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Consider alternative therapy",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0625",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Consider alternative therapy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 200 mcg/mL (100 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mg/mL (10 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (10 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse via infusion pump",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     20 mg in 100 mL (total volume) (concentration: 200",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     200",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F196776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amikacin, amiodarone, ampicillin, argatroban, atracurium, bivalirudin, bumetanide, calcium chloride, calcium gluconate, caspofungin, cefazolin, cefepime, cefotaxime, ceftazidime, cefuroxime, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diltiazem, dobutamine, dopamine, doripenem, epinephrine, fenoldopam, fentanyl, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, insulin (regular), isoproterenol, labetalol, lorazepam, magnesium sulfate, meropenem, methylprednisolone sodium succinate, metoprolol, metronidazole, micafungin, midazolam, morphine, nesiritide, nicardipine, nitroglycerin, nitroprusside, norepinephrine, oxacillin, pancuronium, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, propranolol, quinidine gluconate, ranitidine, rocuronium, sodium bicarbonate, telavancin, theophylline, thiopental, ticarcillin/clavulanate, tobramycin, torsemide, vancomycin, vasopressin, vecuronium, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, imipenem/cilastin, procainamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, calcium chloride, digoxin, epinephrine, lidocaine, morphine, propranolol, sodium bicarbonate, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term I.V. therapy of acutely-decompensated heart failure",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5224428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inotropic therapy for patients unresponsive to other acute heart failure therapies (eg,  dobutamine); outpatient inotropic therapy for heart transplant candidates; palliation of symptoms in end-stage heart failure patients who cannot otherwise be discharged from the hospital and are not transplant candidates",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Primacor&reg; may be confused with Primaxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Cardiovascular: Ventricular arrhythmia (ectopy 9%, NSVT 3%, sustained ventricular tachycardia 1%, ventricular fibrillation &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Supraventricular arrhythmia (4%), hypotension (3%), angina/chest pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, atrial fibrillation, bronchospasm, hypokalemia, injection site reaction, liver function abnormalities, MI, rash, thrombocytopenia, torsade de pointes, tremor, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to milrinone, inamrinone, or any component of the formulation; concurrent use of inamrinone",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Observe for arrhythmias in this very high-risk patient population.  Ventricular or atrial arrhythmias may persist even after discontinuation of inamrinone especially in patients with renal dysfunction.  Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate. In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Discontinue therapy if dose-related elevations in LFTs and clinical symptoms of hepatotoxicity occur; monitor liver function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Monitor blood pressure/ heart rate closely. Mean arterial pressure decreases by &sim;5% at doses between 0.375-5 mcg/kg/minute and by 17% at 0.75 mcg/kg/minute (includes loading doses ranging between 37.5-75 mcg/kg). Infusion may require reduction in dose or temporary discontinuation if hypotension occurs.  Hypotension may be prolonged especially in patients with renal dysfunction.  Vigorous diuresis may contribute to hypotension; cautious administration of fluids may be required to prevent hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Not recommended in acute MI treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. Hypotension may be prolonged in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term therapy: According to the ACC/AHA 2009 heart failure guidelines, long-term, regularly-scheduled intermittent infusions are strongly discouraged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Monitor fluid status closely; patients may require adjustment of diuretic and electrolyte replacement therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13334385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies; however, increased resorption was reported in some studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Milrinone in Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg/mL 5% (100 mL): $18.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Milrinone Lactate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (20 mL): $13.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F196718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet count, CBC, electrolytes (especially potassium and magnesium), liver function and renal function tests; ECG, CVP, SBP, DBP, heart rate; infusion site",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If pulmonary artery catheter is in place, monitor cardiac index, stroke volume, systemic vascular resistance, pulmonary capillary wedge pressure and pulmonary vascular resistance.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corotrop (AT, CH, CZ, ES, SE);",
"     </li>",
"     <li>",
"      Corotrope (AR, BE, CN, CO, ES, FR, GR, HN, LU, NL, PE, PL, UY, VE);",
"     </li>",
"     <li>",
"      Inovad (ID);",
"     </li>",
"     <li>",
"      Lunan Likang (CL);",
"     </li>",
"     <li>",
"      Milicor (IN);",
"     </li>",
"     <li>",
"      Primacor (AU, BR, GB, HK, IL, IN, KP, MX, MY, NZ, PH, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A selective phosphodiesterase inhibitor in cardiac and vascular tissue, resulting in vasodilation and inotropic effects with little chronotropic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.32-0.45 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: ~2.5 hours; CVVH: 20.1 hours (Taniguchi, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (85% as unchanged drug) within 24 hours; active tubular secretion is a major elimination pathway for milrinone",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 45, 145.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baruch L, Patacsil P, Hameed A, et al, &ldquo;Pharmacodynamic Effects of Milrinone With and Without a Bolus Loading Infusion,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2001, 141(2):266-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/11174341/pubmed\" id=\"11174341\" target=\"_blank\">",
"        11174341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuffe MS, Califf RM, Adams KF Jr, et al, &ldquo;Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(12):1541-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/11911756/pubmed\" id=\"11911756\" target=\"_blank\">",
"        11911756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cusick DA, Pfeifer PB, and Quigg RJ, &ldquo;Effects of Intravenous Milrinone Followed by Titration of High-Dose Vasodilator Therapy on Clinical Outcome and Rehospitalization Rates in Patients With Severe Heart Failure,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1998, 82(9):1060-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/9817482/pubmed\" id=\"9817482\" target=\"_blank\">",
"        9817482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Felker GM, Benza RL, Chandler AB, et al, &ldquo;Heart Failure Etiology and Response to Milrinone in Decompensated Heart Failure: Results From the OPTIME-CHF Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(6):997-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/12651048/pubmed\" id=\"12651048\" target=\"_blank\">",
"        12651048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hatzizacharias A, Makris T, Krespi P, et al, &ldquo;Intermittent Milrinone Effect on Long-Term Hemodynamic Profile in Patients With Severe Congestive Heart Failure,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1999, 138(2 Pt 1):241-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/10426834/pubmed\" id=\"10426834\" target=\"_blank\">",
"        10426834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pamboukian SV, Carere RG, Webb JG, et al, &ldquo;The Use of Milrinone in Pretransplant Assessment of Patients With Congestive Heart Failure and Pulmonary Hypertension,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 1999, 18(4):367-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/10226902/pubmed\" id=\"10226902\" target=\"_blank\">",
"        10226902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevenson LW, &ldquo;Inotropic Therapy for Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(25):1848-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/9854124/pubmed\" id=\"9854124\" target=\"_blank\">",
"        9854124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taniguchi T, Shibata K, Saito S, et al, &ldquo;Pharmacokinetics of Milrinone in Patients With Congestive Heart Failure During Continuous Venovenous Hemofiltration,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2000, 26(8):1089-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/18/3366/abstract-text/11030165/pubmed\" id=\"11030165\" target=\"_blank\">",
"        11030165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9652 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3366=[""].join("\n");
var outline_f3_18_3366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196740\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196770\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196741\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196742\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196743\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196720\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196706\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196723\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472935\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472936\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196776\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196721\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5224428\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196778\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196768\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196726\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196710\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299715\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221703\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196716\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196747\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323415\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196718\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196728\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196709\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196725\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9652|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/22/20835?source=related_link\">",
"      Milrinone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=related_link\">",
"      Milrinone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3367="Causes of female infertility";
var content_f3_18_3367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of female infertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Wendy Kuohung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3367/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/18/3367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is a complex disorder with significant medical, psychosocial, and economic aspects. The etiologies of female infertility will be reviewed here. Evaluation and treatment of female infertility are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link\">",
"     \"Overview of treatment of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes of male infertility are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"     \"Causes of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a World Health Organization (WHO) study of 8500 infertile couples, female factor infertility was reported in 37 percent of infertile couples in developed countries, male factor infertility in 8 percent, and both male and female factor infertility in 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/1\">",
"     1",
"    </a>",
"    ]. The remaining couples had unexplained infertility or became pregnant during the study. The most common identifiable female factors, which accounted for 81 percent of female infertility, were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ovulatory disorders (25 percent)",
"     </li>",
"     <li>",
"      Endometriosis (15 percent)",
"     </li>",
"     <li>",
"      Pelvic adhesions (12 percent)",
"     </li>",
"     <li>",
"      Tubal blockage (11 percent)",
"     </li>",
"     <li>",
"      Other tubal abnormalities (11 percent)",
"     </li>",
"     <li>",
"      Hyperprolactinemia (7 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18439130\">",
"    <span class=\"h1\">",
"     OVARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ovulatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequent ovulation (oligoovulation) or absent ovulation (anovulation) results in infertility because an oocyte is not available every month for fertilization. Women who report monthly menses and molimina (breast tenderness, dysmenorrhea, bloating) are typically ovulatory. If menses and molimina are irregular or absent, pregnancy or another condition associated with",
"    <span class=\"nowrap\">",
"     oligoovulation/anovulation",
"    </span>",
"    is likely. Potential causes are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79628 \" href=\"UTD.htm?12/36/12876\">",
"     table 1",
"    </a>",
"    ) (see individual topic reviews for more information on each disorder).",
"   </p>",
"   <p>",
"    The World Health Organization has classified anovulation into three main groups, and recognizes hyperprolactinemia as additional etiology (",
"    <a class=\"graphic graphic_table graphicRef69734 \" href=\"UTD.htm?29/15/29947\">",
"     table 2",
"    </a>",
"    ). This system is useful for defining and treating anovulatory disorders according to the underlying endocrine dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oocyte aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is an important factor affecting a woman's fertility (",
"    <a class=\"graphic graphic_figure graphicRef50854 \" href=\"UTD.htm?11/47/12031\">",
"     figure 1",
"    </a>",
"    ). The decrease in fecundability with aging is likely due to a decline in both the quantity and quality of the oocytes.",
"   </p>",
"   <p>",
"    The germ cell complement of the ovary reaches its apex of 6 to 7 million follicles in the midgestation female fetus, followed by a steady attrition from 1 to 2 million follicles at birth to 300,000 follicles at the onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of follicle loss accelerates after the woman reaches her mid-thirties [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .) Other insults to the ovary such as cigarette smoking, radiation, chemotherapy, and autoimmune disease also accelerate follicular loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Women with a depleted ovarian follicle pool may continue to ovulate regularly, but have infertility due to the poor quality of oocytes remaining in the terminal follicular pool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The loss of oocyte quality as a woman ages is thought to be due to an increase in meiotic nondisjunction. Hypothesized mechanisms involve differences between germ cells when formed during fetal life, damage in germ cells that accumulates over the course of a woman&rsquo;s life, or age-related changes in the quality of the granulosa cells surrounding the oocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FALLOPIAN TUBE ABNORMALITIES/PELVIC ADHESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal disease and pelvic adhesions prevent normal transport of the oocyte and sperm through the fallopian tube. The primary cause of tubal factor infertility is pelvic inflammatory disease caused by pathogens such as chlamydial or gonorrhea. Other conditions that may interfere with tubal transport include severe endometriosis (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Endometriosis'",
"    </a>",
"    below), adhesions from previous surgery or nontubal infection (eg, appendicitis, inflammatory bowel disease), pelvic tuberculosis, and salpingitis isthmica nodosa (ie, diverticulosis of the fallopian tube). Proximal tubal blockage may result from plugs of mucus and amorphous debris or spasm of the uterotubal ostium, but does not reflect true anatomic occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with distal tubal obstruction may develop hydrosalpinges, which decrease the success rate of in vitro fertilization (IVF). In addition to obstruction to sperm migration, hydrosalpinges appear to reduce fertility by retrograde flow of tubal contents into the endometrial cavity, which creates a hostile environment to implantation of an embryo. Removal of the hydrosalpinges increases the success of IVF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link&amp;anchor=H11#H11\">",
"     \"Reproductive surgery for female infertility\", section on 'Salpingectomy before in vitro fertilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18439152\">",
"    <span class=\"h1\">",
"     UTERUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired implantation, either mechanical or due to reduced endometrial receptivity, are the basis of uterine causes of infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Uterine leiomyomata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomata are common benign smooth muscle monoclonal tumors. A meta-analysis of studies comparing women with infertility and leiomyomata versus infertile controls showed that only leiomyomata with a submucosal or intracavitary component were associated with lower pregnancy and implantation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/10\">",
"     10",
"    </a>",
"    ]. When women with submucous myomas underwent myomectomy, pregnancy rates increased significantly compared to infertile controls. Thus, it appears that only those fibroids with a submucosal or an intracavitary component are associated with decreased fecundability. The likely mechanism is inhibition to normal implantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Uterine anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine abnormalities are thought to cause infertility by interfering with normal implantation. M&uuml;llerian anomalies are a significant cause of recurrent pregnancy loss (RPL), with the septate uterus associated with the poorest reproductive outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/11\">",
"     11",
"    </a>",
"    ]. Other structural abnormalities associated with infertility include endometrial polyps, and synechiae from prior pregnancy-related curettage. However, data establishing a causal link between these uterine abnormalities and infertility are lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18439229\">",
"    <span class=\"h2\">",
"     Luteal phase defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Luteal phase defect refers to abnormalities of the corpus luteum that result in inadequate production of progesterone, which is necessary for making the endometrium receptive to implantation.",
"   </p>",
"   <p>",
"    Diagnosis of a luteal phase defect is based upon the finding of two consecutive endometrial biopsy specimens showing histology more than two days out-of-phase with the actual biopsy date [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/12\">",
"     12",
"    </a>",
"    ]. The delayed endometrial maturation is thought to be caused by a deficiency of corpus luteum progesterone production, either in amount or duration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/13\">",
"     13",
"    </a>",
"    ]. However, up to 50 percent of normal fertile women may have a two-day lag in endometrial maturation on a single biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/14\">",
"     14",
"    </a>",
"    ]. The high proportion of out-of-phase biopsies among fertile women occurs, at least in part, because menstrual dating is not a highly accurate method of dating ovulation; ovulatory dating by sonography and measurement of the LH surge yield the fewest biopsies with delayed maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of female infertility\", section on 'Endometrial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most experts believe that endometrial dating is not useful for evaluating or guiding treatment of infertile women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ENDOMETRIOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms which decrease fertility in women with endometriosis include anatomic distortion from pelvic adhesions, damage to ovarian tissue by endometrioma formation and surgical resection, and the production of substances such as cytokines and growth factors which impair the normal processes of ovulation, fertilization, and implantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CERVICAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal midcycle cervical mucus facilitates the transport of sperm. Congenital malformations and trauma to the cervix (including surgery) may result in stenosis and inability of the cervix to produce normal mucus, thereby impairing fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196627344\">",
"    <span class=\"h1\">",
"     INHERITED THROMBOPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilias do not appear to be related to unexplained infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15951438\">",
"    <span class=\"h1\">",
"     IMMUNE FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiphospholipid syndrome may lead to immunological rejection of the early pregnancy or placental damage. Evaluation for this disorder depends upon the patient's medical and family history and whether infertility is related to recurrent early pregnancy failure (work-up indicated) or failure to conceive (work-up not indicated) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1916908512\">",
"    <span class=\"h2\">",
"     Antibodies unrelated to APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased frequency of abnormal immune test results in women with early reproductive failure has been reported repeatedly; however, the most rigorous studies have not proven a cause and effect between these phenomena [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/24\">",
"     24",
"    </a>",
"    ]. Immune testing of infertile couples in clinical practice is not supported by existing data and treatments administered to address abnormal results on immunological testing solely for the purpose of improving fertility have not been proven to be beneficial and may cause harm.",
"   </p>",
"   <p>",
"    Women with some autoimmune diseases are at increased risk of infertility unrelated to direct effects of these antibodies on fertilization and implantation. For example, premature ovarian failure has also been described in women with systemic lupus erythematosus&nbsp;and myasthenia gravis. Autoimmune oophoritis may occur as part of type I and type II syndromes of polyglandular autoimmune failure, which are associated with autoantibodies to multiple endocrine and other organs. Women with untreated celiac disease may have an increased frequency of reproductive abnormalities: later menarche, earlier menopause, secondary amenorrhea, recurrent miscarriage, and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/25-27\">",
"     25-27",
"    </a>",
"    ] .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENETIC CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertile couples have been shown to have a higher prevalence of karyotype abnormalities (trisomies, mosaics, translocations, etc) than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/28\">",
"     28",
"    </a>",
"    ]. The frequency varies according to the cause of infertility and clinical history. The most common aneuploidies associated with infertility are 45, X (Turner syndrome) in women and 47, XXY (Klinefelter syndrome) in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary hypogonadism in males\", section on 'Klinefelter's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individual genes that affect fecundity have been identified, including KAL1 (Kallmann's syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/29\">",
"     29",
"    </a>",
"    ], GnRH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], FSH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/32\">",
"     32",
"    </a>",
"    ], beta subunit of FSH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/33\">",
"     33",
"    </a>",
"    ], LH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/34\">",
"     34",
"    </a>",
"    ], FMR1 (fragile X syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/35\">",
"     35",
"    </a>",
"    ], SF1, DAX1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/36\">",
"     36",
"    </a>",
"    ], LEP (leptin) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/37\">",
"     37",
"    </a>",
"    ], LEP receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/38\">",
"     38",
"    </a>",
"    ], GPR54 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], and FGFR1 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3367/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LIFESTYLE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifestyle factors which may contribute to subfertility are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     UNEXPLAINED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexplained infertility is the diagnosis given to couples after a thorough evaluation has not revealed a cause. Many cases of unexplained infertility may be due to small contributions from multiple factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link\">",
"     \"Unexplained infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"       \"Patient information: Infertility in women (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=see_link\">",
"       \"Patient information: Infertility in couples (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"       \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"       \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of female infertility include: ovulatory dysfunction (age or non-age related), fallopian tube abnormalities (related to pelvic adhesions and infection), endometriosis, uterine abnormalities (congenital or acquired), and cervical factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO Technical Report Series. Recent Advances in Medically Assisted Conception Number 820, 1992, pp 1-111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/2\">",
"      Baker TG. Radiosensitivity of mammalian oocytes with particular reference to the human female. Am J Obstet Gynecol 1971; 110:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/3\">",
"      Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/4\">",
"      Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod 1995; 10:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/5\">",
"      Jick H, Porter J. Relation between smoking and age of natural menopause. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Lancet 1977; 1:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/6\">",
"      Cramer DW, Barbieri RL, Xu H, Reichardt JK. Determinants of basal follicle-stimulating hormone levels in premenopausal women. J Clin Endocrinol Metab 1994; 79:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/7\">",
"      Westhoff C, Murphy P, Heller D. Predictors of ovarian follicle number. Fertil Steril 2000; 74:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/8\">",
"      Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/9\">",
"      Practice Committee of the American Society for Reproductive Medicine. Committee opinion: role of tubal surgery in the era of assisted reproductive technology. Fertil Steril 2012; 97:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/10\">",
"      Pritts EA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001; 56:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/11\">",
"      Homer HA, Li TC, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril 2000; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/12\">",
"      Peters AJ, Lloyd RP, Coulam CB. Prevalence of out-of-phase endometrial biopsy specimens. Am J Obstet Gynecol 1992; 166:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/13\">",
"      Soules MR, McLachlan RI, Ek M, et al. Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle. J Clin Endocrinol Metab 1989; 69:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/14\">",
"      Davis OK, Berkeley AS, Naus GJ, et al. The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies. Fertil Steril 1989; 51:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/15\">",
"      Shoupe D, Mishell DR Jr, Lacarra M, et al. Correlation of endometrial maturation with four methods of estimating day of ovulation. Obstet Gynecol 1989; 73:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/16\">",
"      Balasch J, F&aacute;bregues F, Creus M, Vanrell JA. The usefulness of endometrial biopsy for luteal phase evaluation in infertility. Hum Reprod 1992; 7:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/17\">",
"      Coutifaris C, Myers ER, Guzick DS, et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril 2004; 82:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/18\">",
"      Casadei L, Puca F, Privitera L, et al. Inherited thrombophilia in infertile women: implication in unexplained infertility. Fertil Steril 2010; 94:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/19\">",
"      Coulam CB, Jeyendran RS. Thrombophilic gene polymorphisms are risk factors for unexplained infertility. Fertil Steril 2009; 91:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/20\">",
"      Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update 2008; 14:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/21\">",
"      Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril 2009; 92:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/22\">",
"      Hornstein MD, Davis OK, Massey JB, et al. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000; 73:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/23\">",
"      Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril 2008; 90:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/24\">",
"      Kallen CB, Arici A. Immune testing in fertility practice: truth or deception? Curr Opin Obstet Gynecol 2003; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/25\">",
"      Meloni GF, Dessole S, Vargiu N, et al. The prevalence of coeliac disease in infertility. Hum Reprod 1999; 14:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/26\">",
"      Collin P, Vilska S, Heinonen PK, et al. Infertility and coeliac disease. Gut 1996; 39:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/27\">",
"      Jackson JE, Rosen M, McLean T, et al. Prevalence of celiac disease in a cohort of women with unexplained infertility. Fertil Steril 2008; 89:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/28\">",
"      Clementini E, Palka C, Iezzi I, et al. Prevalence of chromosomal abnormalities in 2078 infertile couples referred for assisted reproductive techniques. Hum Reprod 2005; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/29\">",
"      Christensen, RB, Matsumoto, AM, Bremmer, WJ. Idiopathic hypogonadotropic hypogonadism with anosmia (Kallmann syndrome). Endocrinologist 1992; 2:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/30\">",
"      de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/31\">",
"      Layman LC, Cohen DP, Jin M, et al. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998; 18:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/32\">",
"      Aittom&auml;ki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/33\">",
"      Phillip M, Arbelle JE, Segev Y, Parvari R. Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone. N Engl J Med 1998; 338:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/34\">",
"      Toledo SP, Brunner HG, Kraaij R, et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46,XX female. J Clin Endocrinol Metab 1996; 81:3850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/35\">",
"      Schwartz CE, Dean J, Howard-Peebles PN, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 1994; 51:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/36\">",
"      Achermann JC, Meeks JJ, Jameson JL. Phenotypic spectrum of mutations in DAX-1 and SF-1. Mol Cell Endocrinol 2001; 185:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/37\">",
"      Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/38\">",
"      Cl&eacute;ment K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/39\">",
"      de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003; 100:10972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/40\">",
"      Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3367/abstract/41\">",
"      Dod&eacute; C, Levilliers J, Dupont JM, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003; 33:463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5408 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3367=[""].join("\n");
var outline_f3_18_3367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18439130\">",
"      OVARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ovulatory disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oocyte aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FALLOPIAN TUBE ABNORMALITIES/PELVIC ADHESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18439152\">",
"      UTERUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Uterine leiomyomata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Uterine anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18439229\">",
"      Luteal phase defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ENDOMETRIOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CERVICAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196627344\">",
"      INHERITED THROMBOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15951438\">",
"      IMMUNE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1916908512\">",
"      Antibodies unrelated to APS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENETIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LIFESTYLE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      UNEXPLAINED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5408|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/47/12031\" title=\"figure 1\">",
"      Live births per embryo transfer by maternal age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/36/12876\" title=\"table 1\">",
"      Causes anovulation oligoovulati",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/15/29947\" title=\"table 2\">",
"      WHO Classification of anovulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=related_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=related_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3368="Pancreatic cystic neoplasms";
var content_f3_18_3368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pancreatic cystic neoplasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3368/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3368/contributors\">",
"     Asif Khalid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3368/contributors\">",
"     Kevin McGrath, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3368/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3368/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3368/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/18/3368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cysts are diagnosed with increasing frequency because of the widespread use of cross-sectional imaging. As an example, pancreatic cysts were detected in 1.2 percent of more than 24,000 patients who underwent abdominal imaging with computed tomography or magnetic resonance imaging at a major medical center [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatic cysts can either be neoplastic (eg, intraductal papillary mucinous neoplasms) or non-neoplastic. Accurate cyst categorization is important, since non-neoplastic cysts require treatment only if symptomatic, whereas some of the pancreatic cystic neoplasms have significant malignant potential and should be resected.",
"   </p>",
"   <p>",
"    This topic will review issues related to pancreatic cystic neoplasms, including serous cystic tumors, mucinous cystic neoplasms, intraductal papillary mucinous neoplasms, and solid pseudopapillary neoplasms. The classification of pancreatic cysts, the diagnosis and management of pancreatic pseudocysts, and a detailed discussion of intraductal papillary mucinous neoplasms of the pancreas are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link\">",
"       \"Classification of pancreatic cysts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"       \"Diagnosis and management of pseudocysts of the pancreas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=see_link\">",
"       \"Endoscopic management of pseudocysts of the pancreas: Technique\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=see_link\">",
"       \"Endoscopic management of pseudocysts of the pancreas: Efficacy and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF PANCREATIC CYSTIC NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pancreatic cystic neoplasms (PCNs) are detected incidentally when abdominal imaging is performed for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/1\">",
"     1",
"    </a>",
"    ]. PCNs account for more than 50 percent of pancreatic cysts, even in patients with a history of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification of pancreatic cysts\", section on 'Pancreatic cystic neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCNs are categorized using the WHO histological classification (",
"    <a class=\"graphic graphic_table graphicRef69594 \" href=\"UTD.htm?5/20/5452\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. There are four subtypes of PCNs which have varying malignant potential:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serous cystic tumors",
"     </li>",
"     <li>",
"      Mucinous cystic neoplasms",
"     </li>",
"     <li>",
"      Intraductal papillary mucinous neoplasms (IPMNs)",
"     </li>",
"     <li>",
"      Solid pseudopapillary neoplasms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The key demographic and clinical features of PCNs are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef57759 \" href=\"UTD.htm?38/0/38925\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The relative frequencies of the different PCNs were examined in a retrospective series of 851 patients undergoing surgical resection for a cystic neoplasm of the pancreas between 1978 and 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/5\">",
"     5",
"    </a>",
"    ]. Intraductal papillary mucinous neoplasms accounted for 38 percent of lesions, mucinous cystic neoplasms for 23 percent, serous cystic tumors for 16 percent, and solid pseudopapillary neoplasms for 3 percent. When only the 376 patients who had surgery between 2005 and 2011 were considered, 49 percent had intraductal papillary mucinous neoplasms, 16 percent had mucinous cystic neoplasms, 12 percent had serous cystic tumors, and 5 percent had solid pseudopapillary neoplasms. &nbsp;However, this series is subject to referral bias, as it only evaluated resected PCNs. Most branch duct IPMNs and serous cystadenomas do not require resection; thus the relative frequency of these lesions may have been underestimated.",
"   </p>",
"   <p>",
"    It should be noted that pancreatic neuroendocrine tumors occasionally appear cystic and should be considered in the differential diagnosis of PCNs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145107#H12145107\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with pancreatic cysts are asymptomatic, and the cysts are discovered incidentally when abdominal imaging is obtained for unrelated indications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/1\">",
"     1",
"    </a>",
"    ]. When symptoms are present, they are often nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serous cystic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serous cystic tumors can cause symptoms due to cyst enlargement and resultant space occupation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Cysts that are greater than 4 cm in size are more likely to cause symptoms or findings on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/9\">",
"     9",
"    </a>",
"    ], which include abdominal discomfort, a palpable mass, and bile duct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastric outlet obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mucinous cystic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous cystic neoplasms can present with abdominal pain, recurrent pancreatitis, gastric outlet obstruction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a palpable mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/10\">",
"     10",
"    </a>",
"    ]. Jaundice",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss are more common with malignant lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intraductal papillary mucinous neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the other pancreatic cystic lesions, many patients with intraductal papillary mucinous neoplasms (IPMNs) are asymptomatic. However, some patients have a longstanding history of recurrent acute pancreatitis or symptoms suggestive of chronic pancreatitis, which result from intermittent obstruction of the pancreatic duct with mucus plugs. Other manifestations include back pain, jaundice, weight loss, anorexia, steatorrhea, and diabetes and are harbingers of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link&amp;anchor=H5507120#H5507120\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Solid pseudopapillary neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, approximately 80 percent of patients with solid pseudopapillary neoplasms (SPNs) were symptomatic. However, incidental detection of SPNs is becoming more common with widespread use of cross-sectional imaging, and it now accounts for up to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/11\">",
"     11",
"    </a>",
"    ]. The most common symptom is abdominal pain, followed by nausea, vomiting, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/11\">",
"     11",
"    </a>",
"    ]. Other symptoms that occur less frequently include gastrointestinal obstruction, anemia, jaundice, and pancreatitis. Patients may also have a palpable mass, which is the most common presentation in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major challenge in the evaluation of pancreatic cystic neoplasms (PCNs) is identifying lesions with malignant potential. Cysts with malignant potential include mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and solid pseudopapillary neoplasms (SPNs). There is little to no malignant potential with serous cystadenomas. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Malignant potential and management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both symptomatic and asymptomatic pancreatic cysts require evaluation, even in patients who have had pancreatitis, since some pancreatic cystic neoplasms can cause pancreatitis, and more than half of cysts in patients with pancreatitis are PCNs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a cyst is less than 5 mm in largest diameter, asymptomatic, and lacks concerning features on imaging (eg, mural nodularity), it is reasonable to repeat cross-sectional imaging in one year. Additional evaluation (eg, endoscopic ultrasound) is required for most other cysts and for patients with small cysts who develop symptoms or cyst enlargement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiologic and endoscopic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cysts are most often detected with computed tomography (CT) or magnetic resonance imaging (MRI), which in some cases reveals pathognomonic findings that are sufficient for determining the type of cyst. In many cases, however, additional diagnostic studies are required.",
"   </p>",
"   <p>",
"    Endoscopic ultrasound (EUS) provides high quality imaging of the pancreas as well as the opportunity to sample pancreatic lesions through fine-needle aspiration (EUS-FNA), which increases diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/12\">",
"     12",
"    </a>",
"    ]. The cyst fluid obtained via EUS-FNA can be analyzed for cytology, tumor markers, and molecular markers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of intraductal EUS may also increase diagnostic accuracy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=see_link&amp;anchor=H21#H21\">",
"     \"Intraductal ultrasound of the pancreaticobiliary ductal system\", section on 'Mucin producing tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic retrograde cholangiopancreatography (ERCP) was traditionally used in the evaluation of IPMNs. However, it has largely been replaced with other imaging modalities, such as magnetic resonance cholangiopancreatography, EUS, and multidetector CT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5511892#H5511892\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Endoscopic retrograde cholangiopancreatography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS-FNA of PCNs often yields a paucicellular specimen, which limits the yield of cytology. Cytological examination of the cystic fluid may permit diagnosis if either glycogen-rich cells (serous cystadenoma) or mucin-containing cells (MCNs and IPMNs) are present, but the sensitivity is low.",
"   </p>",
"   <p>",
"    In a prospective study of 341 patients undergoing EUS-FNA of pancreatic cysts, 112 had their cysts surgically resected. When the cytology results were compared with the histologic findings, the sensitivity of cytology for detecting mucinous lesions (MCNs and IPMNs) was 35 percent, and the specificity was 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of cytology brushings may improve the yield of EUS-FNA for diagnosing mucinous lesions. In a study of 37 patients with 39 cystic lesions measuring at least 20 mm in diameter, the yield of cytology brushings for mucinous epithelium was compared with FNA in patients with suspected mucinous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/13\">",
"     13",
"    </a>",
"    ]. Cytobrushings were significantly more likely to detect intracellular mucin than was FNA (62 versus 23 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoembryonic antigen (CEA) is the best studied and most accurate tumor marker for diagnosing a mucinous pancreatic cystic neoplasm (PCN), although the accuracy and the cut-off level vary among laboratories. Approximately 0.2 to 1.0 mL of cyst fluid is required to run the test.",
"   </p>",
"   <p>",
"    Studies have attempted to determine the optimal cut-off for CEA predicting a mucinous cyst. In one study, a cut-off of 192",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had a sensitivity of 73 percent for diagnosing a mucinous PCN and a specificity of 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/12\">",
"     12",
"    </a>",
"    ]. A larger study from the same institution reports a cut-off of 110",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    having a sensitivity of 81 percent and a specificity of 98 percent for diagnosing a mucinous cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/14\">",
"     14",
"    </a>",
"    ]. In general, a higher CEA level yields a higher likelihood that a cyst is mucinous [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there is no direct correlation of CEA concentration with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular markers and cyst fluid DNA are other methods that have been used to differentiate mucinous PCNs from nonmucinous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In one study, the presence of a k-ras mutation in cyst fluid had a sensitivity of 45 percent for diagnosing a mucinous PCN, with a specificity of 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, a high amount of DNA with high amplitude allelic loss of tumor suppressor genes (over 80 percent of the cyst fluid DNA affected) was associated with malignancy, with a sensitivity of 70 percent and a specificity of 85 percent.",
"   </p>",
"   <p>",
"    Further studies are required to validate these results and to determine if molecular markers can differentiate intraductal papillary mucinous neoplasms from mucinous cystic neoplasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Findings associated with specific cysts",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Serous cystic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT imaging of serous cystic tumors typically reveals a well-demarcated multicystic lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66608 \" href=\"UTD.htm?21/19/21810\">",
"     image 1",
"    </a>",
"    ). A central scar or \"sunburst\" calcification is visible in up to 20 percent of serous cystadenomas (SCAs) and is considered pathognomonic. The microcystic variant of SCAs can mimic a solid mass on CT.",
"   </p>",
"   <p>",
"    EUS often demonstrates a honeycomb appearance with the microcystic variety (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55761 \" href=\"UTD.htm?41/24/42371\">",
"     image 2",
"    </a>",
"    ). The oligocystic version is comprised of fewer, larger cysts and can be difficult to distinguish from MCN or branch duct IPMN, necessitating EUS-FNA. EUS-FNA of targeted cystic compartments reveals a thin fluid, which is often bloody. Cytologic analysis reveals the cuboidal glycogen-staining cells characteristic of a serous cystic neoplasm in less than 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The cyst fluid CEA level is typically low in SCAs (&lt;5",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mucinous cystic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced CT is the test of choice to diagnose mucinous cystic neoplasms (MCNs). MCNs classically appear as a septated cystic lesion, although they can be unilocular (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65253 \" href=\"UTD.htm?29/41/30353\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/21\">",
"     21",
"    </a>",
"    ]. The cyst is lined by a mucinous epithelium with variable atypia and contains eccentric calcifications in up to 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings associated with malignant transformation in MCNs include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Larger size (5 cm or larger in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/24\">",
"       24",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      A thickened or irregular cyst wall",
"     </li>",
"     <li>",
"      An internal solid component or mass",
"     </li>",
"     <li>",
"      Possibly calcification of the cyst wall",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EUS-FNA permits further characterization and fluid analysis if the diagnosis remains in doubt (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67523 \" href=\"UTD.htm?11/39/11889\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/12,25\">",
"     12,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intraductal papillary mucinous neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation for intraductal papillary mucinous neoplasms is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Solid pseudopapillary neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of a mixed solid and cystic pancreatic lesion on cross-sectional imaging in a young woman is suggestive of a solid pseudopapillary neoplasm (SPN). On magnetic resonance imaging the lesions may appear as well-demarcated solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/26\">",
"     26",
"    </a>",
"    ]. In a study of MRI characteristics of small solid tumors of the pancreas, SPN had significantly lower signal intensity on T1-weighted images, higher signal intensity on T2-weighted images, and had early heterogeneous and progressive enhancement on MRI compared with adenocarcinomas and endocrine tumors. However, it is unclear if cystic and mixed solid and cystic SPN will have the same MRI characteristics.",
"   </p>",
"   <p>",
"    The characteristic appearance on EUS is a well-demarcated, echo-poor, solid-appearing mass, although it can also appear as a mixed solid and cystic lesion or a purely cystic lesion. Irregular calcifications are present in up to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EUS-FNA cytologic analysis reveals characteristic branching papillae with myxoid stroma, best seen in cellblock material [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/28\">",
"     28",
"    </a>",
"    ]. Cytology is diagnostic in 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/27\">",
"     27",
"    </a>",
"    ]. Special stains, including vimentin, CD10 and beta-catenin, may be required to differentiate an SPN from a pancreatic neuroendocrine tumor (eg, insulinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MALIGNANT POTENTIAL AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pancreatic cystic neoplasms (PCNs) is reviewed in practice guidelines published in 2007 by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/30\">",
"     30",
"    </a>",
"    ], and the discussion that follows is consistent with these guidelines.",
"   </p>",
"   <p>",
"    In general, surgery is indicated for lesions with malignant potential, including mucinous cystic neoplasms, main duct intraductal papillary mucinous neoplasms (IPMNs), and solid pseudopapillary neoplasms. The management of side branch IPMNs continues to evolve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510671#H5510671\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of malignancy increases with size in PCNs with malignant potential (eg, IPMNs and mucinous cystic neoplasms). This was demonstrated in a study of 78 patients in whom lesions less than 3 cm in size were malignant in less than 5 percent of cases, lesions between 3 and 5 cm were malignant in about 15 percent, and lesions greater than 5 cm were malignant in more than 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions in the body or tail of the pancreas require a distal pancreatectomy, while those in the head of the gland are resected by pancreaticoduodenectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2569?source=see_link\">",
"     \"Distal pancreatectomy: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=see_link\">",
"     \"Pancreaticoduodenectomy (Whipple procedure): Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serous cystic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the diagnosis of a serous cystadenoma (SCA) is made with certainty, management is determined by the presence of symptoms. Asymptomatic lesions can be observed, as malignant transformation into serous cystadenocarcinoma is exceedingly rare, with only a few case reports in existence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/32\">",
"     32",
"    </a>",
"    ]. In our practice, cross-sectional imaging is only repeated if symptoms develop.",
"   </p>",
"   <p>",
"    Resection is indicated for symptomatic SCAs, or if the diagnosis is in doubt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mucinous cystic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous cystic neoplasms (MCNs) have significant malignant potential. In two series, each with 56 patients with MCNs, carcinoma (noninvasive plus invasive) was present in 11 and 38 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is excellent if the MCN is removed prior to invasion. As a result, resection is recommended for MCNs in patients with acceptable surgical risk. Surveillance following surgery is not necessary since these lesions do not appear to recur [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a patient who is not a surgical candidate and has a small, incidentally discovered lesion, we do not recommend follow-up. If the lesion has significant malignant potential or is symptomatic, endoscopic ultrasound-guided alcohol ablation may become an option in the future as more data accumulate. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Experimental methods'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intraductal papillary mucinous neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant potential and management of intraductal papillary mucinous neoplasms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510671#H5510671\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Solid pseudopapillary neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant potential of solid pseudopapillary neoplasms (SPNs) has not been well studied. In a series of 62 patients, nine (15 percent) had malignant SPNs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/35\">",
"     35",
"    </a>",
"    ]. No factors were identified that predicted malignancy.",
"   </p>",
"   <p>",
"    Malignant solid pseudopapillary neoplasms (SPNs) can be cured when completely excised, and prolonged survival can be seen even in the presence of metastatic disease with surgical debulking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Given the lesion's malignant potential, combined with its good prognosis if resected, the finding of a pancreatic mixed solid and cystic lesion in a young woman on CT or MRI should lead to resection in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cysts of uncertain etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients whose cystic lesions cannot be diagnosed with certainty is unclear. Most experienced pancreatologists and pancreatic surgeons recommend resection for even moderately suspicious lesions in the body or tail of the pancreas, and for highly suspicious lesions in the head of the gland.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Experimental methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic cyst ablation methods, in which the cyst is injected with ethanol or chemotherapeutic agents during endoscopic ultrasound, have been described in a small number of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial report focused on 25 patients in whom various concentrations of ethanol were used, ranging from 5 to 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/38\">",
"       38",
"      </a>",
"      ]. In 23 patients with adequate follow-up, eight (35 percent) had complete resolution of the cysts. Five patients underwent subsequent surgical resection and were found to have variable ablation of the cyst epithelium. There was a non-significant trend toward increased efficacy of ablation with ethanol concentrations of 50 percent or more.",
"     </li>",
"     <li>",
"      In another report, ethanol at a concentration of 88 to 99 percent was combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      injection in 14 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/39\">",
"       39",
"      </a>",
"      ]. After a median follow-up of nine months, 11 of 14 patients had complete cyst resolution. The only significant complication was mild pancreatitis in one patient.",
"     </li>",
"     <li>",
"      A third study looked at 47 patients with unilocular or oligolocular cysts who underwent endoscopic ultrasound with fine needle aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3368/abstract/40\">",
"       40",
"      </a>",
"      ].The cysts were lavaged with ethanol followed by injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      . A complete response was observed in 29 patients (62 percent), a partial response in 6 patients (13 percent), and persistent cysts in 12 patients (26 percent). Complications included mild pancreatitis and splenic vein obliteration. It should be noted that only four patients had surgical pathology correlation, thus it remains unknown whether injection therapy completely ablated all premalignant cyst epithelium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These techniques may hold promise for the treatment of symptomatic cysts or cysts with malignant potential. However, the safety and efficacy of these approaches continues to be examined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many pancreatic cysts are discovered incidentally when abdominal imaging is obtained for unrelated indications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four subtypes of pancreatic cystic neoplasms (PCNs) with varying malignant potential (",
"      <a class=\"graphic graphic_table graphicRef69594 \" href=\"UTD.htm?5/20/5452\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57759 \" href=\"UTD.htm?38/0/38925\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serous cystic tumors",
"     </li>",
"     <li>",
"      Mucinous cystic neoplasms (MCNs)",
"     </li>",
"     <li>",
"      Intraductal papillary mucinous neoplasms (IPMNs)",
"     </li>",
"     <li>",
"      Solid pseudopapillary neoplasms (SPNs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serous cystic tumors have almost no malignant potential, whereas the mucin-producing PCNs (MCNs and IPMNs) and SPNs do. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link\">",
"       \"Classification of pancreatic cysts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some cases, computed tomography or magnetic resonance imaging will reveal pathognomonic findings that are sufficient for determining the type of cyst present. Frequently, however, additional diagnostic studies are required. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic ultrasound (EUS) provides high quality imaging of the pancreas and the opportunity to sample pancreatic lesions through fine-needle aspiration (EUS-FNA), which increases diagnostic accuracy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"       \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cyst fluid obtained via EUS-FNA can be analyzed for cytology, tumor markers, and molecular markers. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cytology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Tumor markers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Molecular markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend resection for MCNs and main duct IPMNs in patients who are surgical candidates (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The management of side branch IPMNs continues to evolve. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Malignant potential and management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510671#H5510671\">",
"       \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend resection for SPNs in patients who are surgical candidates (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Malignant SPNs can be cured if completely excised.",
"     </li>",
"     <li>",
"      Except in patients with symptoms or when the diagnosis is in doubt, we recommend NOT resecting serous cystadenomas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Malignant potential and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/1\">",
"      Spinelli KS, Fromwiller TE, Daniel RA, et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg 2004; 239:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/2\">",
"      Fern&aacute;ndez-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003; 138:427.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Aaltonen, LA, Hamilton, SR (Eds), IARC Press, Lyon, France 2000.",
"    </li>",
"    <li>",
"     Zamboni, G, Kloeppel, G, Hruban, RH, et, al. Mucinous cystic neoplasms of the pancreas. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, Aaltonen, LA, Hamilton, SR (Eds), IARC Press, Lyon, France 2000. p.234.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/5\">",
"      Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 2012; 152:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/6\">",
"      Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen-rich cystadenomas): a clinicopathologic study of 34 cases. Am J Clin Pathol 1978; 69:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/7\">",
"      Pyke CM, van Heerden JA, Colby TV, et al. The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects. Ann Surg 1992; 215:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/8\">",
"      Lundstedt C, Dawiskiba S. Serous and mucinous cystadenoma/cystadenocarcinoma of the pancreas. Abdom Imaging 2000; 25:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/9\">",
"      Tseng JF, Warshaw AL, Sahani DV, et al. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg 2005; 242:413.",
"     </a>",
"    </li>",
"    <li>",
"     Sharma, A. Tumors of the Pancreas. In: Current Diagnosis &amp; Treatment: Gastroenterology, Hepatology, &amp; Endoscopy, Greenberger, NJ, Blumberg, RS, Burakoff, R (Eds), McGraw-Hill, New York 2009. p.318.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/11\">",
"      Romics L Jr, Ol&aacute;h A, Bel&aacute;gyi T, et al. Solid pseudopapillary neoplasm of the pancreas--proposed algorithms for diagnosis and surgical treatment. Langenbecks Arch Surg 2010; 395:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/12\">",
"      Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/13\">",
"      Al-Haddad M, Gill KR, Raimondo M, et al. Safety and efficacy of cytology brushings versus standard fine-needle aspiration in evaluating cystic pancreatic lesions: a controlled study. Endoscopy 2010; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/14\">",
"      Cizginer S, Turner B, Bilge AR, et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas 2011; 40:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/15\">",
"      Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005; 3:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/16\">",
"      Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009; 69:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/17\">",
"      Rockacy MJ, Zahid M, McGrath KM, et al. Association Between KRAS Mutation, Detected in Pancreatic Cyst Fluid, and Long-term Outcomes of Patients. Clin Gastroenterol Hepatol 2013; 11:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/18\">",
"      Frossard JL, Amouyal P, Amouyal G, et al. Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol 2003; 98:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/19\">",
"      Jones EC, Suen KC, Grant DR, Chan NH. Fine-needle aspiration cytology of neoplastic cysts of the pancreas. Diagn Cytopathol 1987; 3:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/20\">",
"      Centeno BA, Lewandrowski KB, Warshaw AL, et al. Cyst fluid cytologic analysis in the differential diagnosis of pancreatic cystic lesions. Am J Clin Pathol 1994; 101:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/21\">",
"      Gress F, Gottlieb K, Cummings O, et al. Endoscopic ultrasound characteristics of mucinous cystic neoplasms of the pancreas. Am J Gastroenterol 2000; 95:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/22\">",
"      Sarr MG, Carpenter HA, Prabhakar LP, et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg 2000; 231:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/23\">",
"      Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999; 23:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/24\">",
"      Reddy RP, Smyrk TC, Zapiach M, et al. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer. Clin Gastroenterol Hepatol 2004; 2:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/25\">",
"      van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005; 62:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/26\">",
"      Yu MH, Lee JY, Kim MA, et al. MR imaging features of small solid pseudopapillary tumors: retrospective differentiation from other small solid pancreatic tumors. AJR Am J Roentgenol 2010; 195:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/27\">",
"      Fasanella KE, McGrath K. Cystic lesions and intraductal neoplasms of the pancreas. Best Pract Res Clin Gastroenterol 2009; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/28\">",
"      Bardales RH, Centeno B, Mallery JS, et al. Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid-pseudopapillary tumor of the pancreas: a rare neoplasm of elusive origin but characteristic cytomorphologic features. Am J Clin Pathol 2004; 121:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/29\">",
"      Jani N, Dewitt J, Eloubeidi M, et al. Endoscopic ultrasound-guided fine-needle aspiration for diagnosis of solid pseudopapillary tumors of the pancreas: a multicenter experience. Endoscopy 2008; 40:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/30\">",
"      Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/31\">",
"      Grobmyer SR, Cance WG, Copeland EM, et al. Is there an indication for initial conservative management of pancreatic cystic lesions? J Surg Oncol 2009; 100:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/32\">",
"      King JC, Ng TT, White SC, et al. Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg 2009; 13:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/33\">",
"      Le Borgne J, de Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 1999; 230:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/34\">",
"      Warshaw AL, Compton CC, Lewandrowski K, et al. Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 1990; 212:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/35\">",
"      Lee SE, Jang JY, Hwang DW, et al. Clinical features and outcome of solid pseudopapillary neoplasm: differences between adults and children. Arch Surg 2008; 143:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/36\">",
"      Chen X, Zhou GW, Zhou HJ, et al. Diagnosis and treatment of solid-pseudopapillary tumors of the pancreas. Hepatobiliary Pancreat Dis Int 2005; 4:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/37\">",
"      Alexandrescu DT, O'Boyle K, Feliz A, et al. Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management. Clin Oncol (R Coll Radiol) 2005; 17:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/38\">",
"      Gan SI, Thompson CC, Lauwers GY, et al. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc 2005; 61:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/39\">",
"      Oh HC, Seo DW, Lee TY, et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc 2008; 67:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3368/abstract/40\">",
"      Oh HC, Seo DW, Song TJ, et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology 2011; 140:172.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5642 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.80-F9E9CAA6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3368=[""].join("\n");
var outline_f3_18_3368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF PANCREATIC CYSTIC NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serous cystic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mucinous cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intraductal papillary mucinous neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Solid pseudopapillary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiologic and endoscopic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Findings associated with specific cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Serous cystic tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mucinous cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intraductal papillary mucinous neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Solid pseudopapillary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MALIGNANT POTENTIAL AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serous cystic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mucinous cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intraductal papillary mucinous neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Solid pseudopapillary neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cysts of uncertain etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Experimental methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5642\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5642|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/19/21810\" title=\"diagnostic image 1\">",
"      Serous cystadenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/24/42371\" title=\"diagnostic image 2\">",
"      EUS microcystic lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/41/30353\" title=\"diagnostic image 3\">",
"      Mucinous cystic neoplasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/39/11889\" title=\"diagnostic image 4\">",
"      EUS mucinous cystic neopl",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5642|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/20/5452\" title=\"table 1\">",
"      WHO classif panc cyst neopl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/0/38925\" title=\"table 2\">",
"      Clin features panc neoplasm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2569?source=related_link\">",
"      Distal pancreatectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/53/39766?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Efficacy and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27655?source=related_link\">",
"      Endoscopic management of pseudocysts of the pancreas: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=related_link\">",
"      Pancreaticoduodenectomy (Whipple procedure): Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3369="Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole";
var content_f3_18_3369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3369/contributors\">",
"     Daniel M Musher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3369/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3369/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/18/3369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus pneumoniae (pneumococcus) is the most common bacterial cause of pneumonia and acute sinusitis, and, along with Haemophilus influenzae, is one of the two most common causes of otitis media and acute exacerbations of chronic bronchitis. The fluoroquinolones (often called quinolones) are widely used to treat adults with these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is also recommended for the treatment of acute sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/1\">",
"     1",
"    </a>",
"    ], acute exacerbation of chronic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/4\">",
"     4",
"    </a>",
"    ], or pneumonia in adult outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) was commonly used to treat these conditions from the mid-1970s to the mid-1990s, but this combination drug has largely fallen out of favor because of the high rate of pneumococcal resistance.",
"   </p>",
"   <p>",
"    Pneumococci were uniformly susceptible to all antibiotics used to treat bacterial infections of the respiratory tract until outbreaks of infection due to antibiotic-resistant pneumococci occurred in South Africa in the late 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Although the responsible organisms were called penicillin-resistant pneumococci, they appeared to have acquired genetic material that encoded resistance both to penicillin and to other commonly used antibiotics. In the ensuing decades, resistance of pneumococci to a variety of antimicrobial agents has evolved from an ominous medical curiosity to a worldwide health problem. Pneumococcal resistance has arisen in a number of clinically relevant classes of antibiotics.",
"   </p>",
"   <p>",
"    The mechanisms of action and resistance and clinical data on the outcome of therapy in respiratory tract infections will be reviewed here for the fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and TMP-SMX. Resistance to the other classes of drugs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FLUOROQUINOLONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluoroquinolones consist of a family of related compounds, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    . Use of these drugs to treat respiratory infection represented a major therapeutic advance. At the time of their introduction, these drugs were uniformly active against S. pneumoniae, as well as Haemophilus, Moraxella, Legionella, Mycoplasma, and Chlamydia spp. Except for generally low (albeit increasing) rates of resistance to the pneumococcus and rare reports of resistance among Haemophilus, they remain so to the present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    is generally thought to be less likely to cure pneumococcal infection than other quinolones, based on its minimal inhibitory concentration (MIC) against most pneumococcal strains, the projected time to achieve serum levels that exceed the MIC, and the height and duration of antibiotic concentrations relative to the MIC. However, there are remarkably few reports of treatment failures with ciprofloxacin in the United States, although it is not regarded as a \"respiratory quinolone&rdquo; by the Infectious Disease Society of America (IDSA) or the American Thoracic Society (ATS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms of action and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quinolones bind topoisomerases, enzymes that govern the twisting and knotting of double-stranded DNA. The principal enzymes involved are gyrase and topoisomerase IV, more specifically, two subunits of gyrase, gyrA and gyrB, and two subunits of topoisomerase IV, parC and parE. By binding these sites, quinolones block enzymatic activity, and bacterial replication cannot take place. The specific site of action of a quinolone is determined by the avidity with which it binds each enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    binds exclusively with topoisomerase IV, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    binds more avidly with topoisomerase IV than with gyrase.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     Moxifloxacin",
"    </a>",
"    reacts more strongly with gyrase.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     Gemifloxacin",
"    </a>",
"    binds avidly with both.",
"   </p>",
"   <p>",
"    Quinolone resistance in S. pneumoniae generally occurs when several mutations in gyrA or parC reduce binding of the drug to the site of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Occasionally, mutations in parE are responsible. Many pneumococcal isolates that are still regarded as susceptible have already acquired one mutation.",
"   </p>",
"   <p>",
"    Resistance is stepwise; the more mutations that have occurred, the more resistant an organism is likely to be. Most quinolone-resistant strains in the United States currently exhibit only a single mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/11\">",
"     11",
"    </a>",
"    ]. Nevertheless, the more highly resistant isolates do tend to exhibit more than one mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/13\">",
"     13",
"    </a>",
"    ], and these isolates are expected to become more prevalent in the future. Isolates with more than one mutation are more likely to remain susceptible to newer quinolones, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    , than to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance studies suggest that no more than 1 percent of S. pneumoniae isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    in the United States; the rate of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    does not exceed 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, there may be foci of higher levels of resistance. A study in assisted living facilities, for example, found 6 percent of all colonizing pneumococci to exhibit resistance to quinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/16\">",
"     16",
"    </a>",
"    ]. In a report from Canada, the prevalence increased from 1.5 percent in 1993 to 1994 to 2.9 percent in 1997 to 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/17\">",
"     17",
"    </a>",
"    ], paralleling the use of quinolones; as the usage of these drugs has been curbed, the rate of resistance appears to have fallen to &lt;2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/14\">",
"     14",
"    </a>",
"    ]. A review summarized concepts about the relationships among proper quinolone use, inappropriate use, and pneumococcal resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher rates of resistance have been noted in other countries. In Croatia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/19\">",
"     19",
"    </a>",
"    ] and Hong Kong [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/20\">",
"     20",
"    </a>",
"    ], 4 to 13 percent of all pneumococci were reported resistant to quinolones, and a study from Asia in 2009 and 2010 found up to 4 percent prevalence of resistance to newer fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/21\">",
"     21",
"    </a>",
"    ]. Within countries that report increasing incidence of resistance, the proportion of resistant isolates is much higher among older subjects and patients with chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, in countries where antimicrobial use is conservative, such as Germany, almost no resistance has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A prospective cohort study of 3339 patients with invasive pneumococcal infection between 1995 and 2002 identified apparent risk factors for the acquisition of fluoroquinolone-resistant pneumococcal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous fluoroquinolone use (odds ratio [OR] 12.1)",
"     </li>",
"     <li>",
"      Current residence in a nursing home (OR 12.9)",
"     </li>",
"     <li>",
"      Nosocomial acquisition of infection (OR 9.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A massive literature on the effects of quinolones in treating respiratory infections includes patients who are proven to have pneumococcal infection and others who are presumed to be infected with S. pneumoniae, often without properly distinguishing among them. Nevertheless, this literature indicates that quinolones are highly effective in treating these conditions, yielding results comparable to or better than other classes of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute exacerbation of chronic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated clinical outcome and eradication of bacterial pathogens in acute infectious exacerbations of chronic bronchitis; as might be expected, pneumococcus has been frequently implicated. Results of treating acute exacerbations of chronic bronchitis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/23\">",
"     23",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/26\">",
"     26",
"    </a>",
"    ] have compared favorably with results using other drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    . Five or seven days of therapy have produced equivalent beneficial effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quinolones have also been extensively evaluated in the treatment of community-acquired pneumonia (CAP); a varying proportion of the patients included were proven to have pneumococcal infection, and a greater number were presumed to be infected. The results of these studies are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter study enrolled 590 patients with pneumonia, including 310 outpatients and 280 inpatients, in a double-blind comparison of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      with or without a macrolide added at the discretion of the treating physician [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/27\">",
"       27",
"      </a>",
"      ]. Fifteen percent were proven to have pneumococcal infection. The clinical and bacteriologic response rates were equally high with either regimen.",
"     </li>",
"     <li>",
"      Treatment studies with other respiratory fluoroquinolones (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      ) have reported success rates that exceed 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/28-31\">",
"       28-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these studies and more cases presented in abstract form or to the United States Food and Drug Administration (FDA) document the efficacy of quinolones for the treatment of pneumonia. However, treatment failures have been reported, albeit in very small numbers, in addition to the in vitro resistance discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/3,32-34\">",
"     3,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DOXYCYCLINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Introduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tetracyclines were discovered in the 1940s and, along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , were the first broad-spectrum antibiotics. For a variety of reasons relating to pharmacokinetics, toxicity and marketing,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    remains the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    of choice. The drug is effective against H. influenzae, M. catarrhalis, Legionella, Mycoplasma and Chlamydia spp, and it was initially uniformly effective against S. pneumoniae, thus explaining its importance in treating respiratory infections. Glycylcyclines, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , regarded as advanced tetracyclines, show great promise against this same list of respiratory pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The literature is remarkable for a paucity of either in vitro or in vivo studies of the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ; this paucity appears to reflect the economics of the medical marketplace more than it reflects interest in or potential efficacy of the drug. Pharmaceutical manufacturers, who support comparative studies of antibiotics, usually choose to compare experimental compounds with drugs that are currently in vogue in order to position them to compete for market share. Some potentially excellent antibiotics are simply not studied, and it can be very difficult to obtain data on them. This principle applies to drugs like doxycycline and TMP-SMX and includes studies in vitro or in vivo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanisms of action and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetracyclines inhibit protein synthesis by binding to the 30S ribosomal unit, specifically blocking the binding of aminoacyl tRNA to the mRNA-ribosome complex. Although regarded as bacteriostatic (which it is for S. aureus),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is bactericidal for the pneumococcus and gram-negative organisms. Resistance is mediated by one or more proteins that bind the drug into vesicles that are then extruded from the bacterium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=see_link\">",
"     \"Tetracyclines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevalence of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the Boston City Hospital in the late 1960s, pneumococci were uniformly susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , with a median minimum inhibitory concentration (MIC) of 0.39",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    (range 0.04 to 0.78",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/37\">",
"     37",
"    </a>",
"    ]. Higher concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    were required to inhibit pneumococci, but no isolates were resistant. Rare cases of infection due to tetracycline-resistant pneumococci were reported in the United States in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/38\">",
"     38",
"    </a>",
"    ]. By that time, a small but measurable percentage of isolates were resistant in England [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/39\">",
"     39",
"    </a>",
"    ] and Scandinavia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/40\">",
"     40",
"    </a>",
"    ]. By the mid-1970s, England had an overall rate of resistance of approximately 13 percent, with regional variation ranging from 2 to 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present in the United States, approximately 20 percent of pneumococcal isolates are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. As expected, this rate is substantially higher among penicillin-resistant than among penicillin-susceptible isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/45\">",
"     45",
"    </a>",
"    ]. There is substantial variation worldwide, with the rate of tetracycline resistance ranging from 6 percent in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/46\">",
"     46",
"    </a>",
"    ] to 25 to 40 percent in many other countries. Studies generally report susceptibility to tetracycline, but, if there is any difference, a slightly higher proportion of isolates will be susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetracyclines were widely used in the 1960s to treat pneumonia and acute exacerbations of chronic bronchitis with apparent good success, although actual data are not easily identified. This was my own experience on the Bellevue Chest Service, 1963 to 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/47\">",
"     47",
"    </a>",
"    ], and is documented in the first article published in the American literature on a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -resistant isolate causing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/38\">",
"     38",
"    </a>",
"    ] and in textbooks on antibiotics written in the 1960s and 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (100 mg twice daily) has largely replaced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    . Doxycycline today is a good drug for the treatment of acute exacerbation of chronic bronchitis or outpatient pneumonia because Haemophilus, Moraxella, Legionella, Mycoplasma, and Chlamydia are almost uniformly susceptible and the drug has &gt;80 percent efficacy against the pneumococcus. One contemporary prospective study of 87 patients hospitalized for moderately severe pneumonia showed that doxycycline compared favorably to other antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/49\">",
"     49",
"    </a>",
"    ]. Although the PORT severity index was not reported, 7 of the 87 had bacteremic disease, suggesting that this group of subjects was representative of hospitalized patients. Similar results were obtained in a study comparing doxycycline to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/50\">",
"     50",
"    </a>",
"    ]. Nevertheless, doxycycline is not recommended for first-line therapy of pneumococcal pneumonia in hospitalized patients; it should be reserved for those whose organism is known to be susceptible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TRIMETHOPRIM-SULFAMETHOXAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) was regarded as excellent therapy specifically for pneumococcal infection as well as more generally for otitis, sinusitis and acute exacerbation of chronic bronchitis until the mid-1990s when it fell out of favor partially due to the increased prevalence of resistance of S. pneumoniae and partially to the development of alternative drugs, such as the newer macrolides and the quinolones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mechanisms of action and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     Trimethoprim",
"    </a>",
"    and sulfamethoxazole block two separate steps in the synthesis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , a needed substrate for bacterial survival. Sulfamethoxazole displaces para-aminobenzoic acid blocking biosynthesis of dihydrofolate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/51\">",
"     51",
"    </a>",
"    ]. Trimethoprim binds avidly to the active site of the bacterial enzyme that reduces dihydrofolate to tetrahydrofolate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/52\">",
"     52",
"    </a>",
"    ]. The concept underlying the use of two drugs was that the combination would prevent the emergence of resistance. (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When TMP-SMX was released, it was touted as a drug to which bacteria would never become resistant, because the mutation rate to each component is 1 in 10",
"    <sup>",
"     7",
"    </sup>",
"    and a double mutation would only occur in 1 of 10",
"    <sup>",
"     14",
"    </sup>",
"    organisms. This prediction proved to be wrong because mutant bacteria simply developed alternative, bypass pathways for folate synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Activity and prevalence of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance of S. pneumoniae to TMP-SMX had clearly been evolving during the 1980s, but it first became prominent in 1986 when a cluster of penicillin-resistant isolates in Brooklyn was also found to be resistant to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/53\">",
"     53",
"    </a>",
"    ]. Two years later, 11 percent of adult carriers and 30 percent of children in a daycare center in North Carolina who were carrying pneumococcus harbored TMP-SMX-resistant isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/54\">",
"     54",
"    </a>",
"    ]. Continued spread and selection of resistance was probably enhanced in children by the extensive use of this combination drug to treat otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/54\">",
"     54",
"    </a>",
"    ] and in adults by the prophylactic use of TMP-SMX in AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-third of all pneumococcal strains in the United States in 1999-2000 showed some level of resistance to TMP-SMX, ranging from 25 percent in the Northeast to 45 percent in the Southeast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/43,56\">",
"     43,56",
"    </a>",
"    ]. The prospective cohort study of 3339 patients with invasive pneumococcal infection cited above identified apparent risk factors for the acquisition of TMP-SMX-resistant pneumococcal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/57\">",
"     57",
"    </a>",
"    ]. These include previous use of TMP-SMX (odds ratio [OR] 4.7),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (OR 3.5), and penicillin (OR 1.7). In many other countries, rates of resistance are even higher, approaching 80 percent in some southeastern Asian countries.",
"   </p>",
"   <p>",
"    With the widespread use of the 7-valent conjugate vaccine, rates of resistance initially declined because the vaccine strains tended to be resistant, but have rebounded as resistant replacement strains have emerged; about 30 percent of pneumococci are resistant to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lower respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the appearance of pneumococcal resistance, TMP-SMX was shown to be efficacious in treating acute exacerbation of chronic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/59\">",
"     59",
"    </a>",
"    ]. Based upon the results of sensitivity tests in vitro and modest amounts of clinical data, this drug was widely used to treat respiratory infections and was especially popular among pulmonologists through the early 1990s. Although TMP-SMX was never approved for the treatment of pneumonia, many practitioners used it for this purpose, and it should have been effective based upon activity against respiratory pathogens. Because of pneumococcal resistance and because of the availability of newer macrolides and quinolones, the drug is now largely out of favor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Upper respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also before the appearance of pneumococcal resistance, TMP-SMX was found to be effective in treating acute sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/60\">",
"     60",
"    </a>",
"    ], although it never became as popular among otolaryngologists as it was among pulmonologists. In the treatment of otitis media, mixed results were obtained in one poorly controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/61\">",
"     61",
"    </a>",
"    ], but a well-designed investigation, supported by culture of middle ear aspirates and carried out before beta-lactamase became a problem in Haemophilus spp., showed TMP-SMX to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3369/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1720181033\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcus pneumoniae (pneumococci) is the most common bacterial cause of pneumonia and acute sinusitis, and, along with Haemophilus influenzae, is one of the two most common causes of otitis media and acute exacerbations of chronic bronchitis. The fluoroquinolones (often called quinolones) are widely used to treat adults with these conditions.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is also recommended for the treatment of acute sinusitis, acute exacerbation of chronic bronchitis, or pneumonia in adult outpatients.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) was commonly used to treat these conditions from the mid-1970s to the mid-1990s, but this combination drug has largely fallen out of favor because of the high rate of pneumococcal resistance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococci were uniformly susceptible to all antibiotics used to treat bacterial infections of the respiratory tract until outbreaks of infection due to antibiotic-resistant pneumococci occurred in South Africa in the late 1970s. Although the responsible organisms were called penicillin-resistant pneumococci, they appeared to have acquired genetic material that encoded resistance both to penicillin and to other commonly used antibiotics. In the ensuing 25 years, resistance of pneumococci to a variety of antimicrobial agents has evolved from an ominous medical curiosity to a worldwide health problem. Pneumococcal resistance has arisen in a number of clinically relevant classes of antibiotics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surveillance studies suggest that no more than 1 percent of S. pneumoniae isolates are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      in the United States; the rate of resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      does not exceed 2 percent. However, there are areas with higher levels of resistance. A study in assisted living facilities, for example, found 6 percent of all colonizing pneumococci to exhibit resistance to quinolones. Higher rates of resistance have been noted in other countries. Despite its low prevalence, quinolone resistance is increasing in the United States and in other countries. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, approximately 20 percent of pneumococcal isolates are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      -resistant. This rate is substantially higher among penicillin-resistant than among penicillin-susceptible isolates. There is substantial variation worldwide, with the rate of tetracycline resistance ranging from 6 percent in Canada to 25 to 40 percent in many other countries. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevalence of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 percent of all pneumococcal strains in the United States are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX), with regional variation, ranging from 25 percent in the Northeast to 45 percent in the Southeast. In many other countries, rates of resistance are even higher, approaching 80 percent in some southeastern Asian countries. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Activity and prevalence of resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/1\">",
"      Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg 2000; 123:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/2\">",
"      American College of Emergency Physicians. Clinical policy for the management and risk stratification of community-acquired pneumonia in adults in the emergency department. Ann Emerg Med 2001; 38:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/3\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/4\">",
"      Dever LL, Shashikumar K, Johanson WG Jr. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs 2002; 11:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/5\">",
"      Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/6\">",
"      Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/7\">",
"      Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/8\">",
"      Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/9\">",
"      Pestova E, Millichap JJ, Siddiqui F, et al. Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 49:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/10\">",
"      Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother 2002; 49:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/11\">",
"      Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002; 46:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/12\">",
"      Jorgensen JH, Weigel LM, Swenson JM, et al. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/13\">",
"      Pletz MW, Shergill AP, McGee L, et al. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2006; 50:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/14\">",
"      Patel SN, McGeer A, Melano R, et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother 2011; 55:3703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/15\">",
"      Thornsberry C, Brown NP, Draghi DC, et al. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgrad Med 2008; 120:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/16\">",
"      Kupronis BA, Richards CL, Whitney CG, Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/17\">",
"      Pletz MW, van der Linden M, von Baum H, et al. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2011; 301:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/18\">",
"      Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/19\">",
"      Pankuch GA, Bozdogan B, Nagai K, et al. Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob Agents Chemother 2002; 46:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/20\">",
"      Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/21\">",
"      Wang H, Chen M, Xu Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. Int J Antimicrob Agents 2011; 38:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/22\">",
"      Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/23\">",
"      Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998; 27:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/24\">",
"      Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999; 43:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/25\">",
"      Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/26\">",
"      Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001; 29:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/27\">",
"      File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965.",
"     </a>",
"    </li>",
"    <li>",
"     Fogarty, C, Grossman, C, Williams, J, et al. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/29\">",
"      Jones RN, Andes DR, Mandell LA, et al. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/30\">",
"      Nicholson SC, Wilson WR, Naughton BJ, et al. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2002; 44:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/31\">",
"      Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/32\">",
"      Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/33\">",
"      Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002; 22:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/34\">",
"      Anderson KB, Tan JS, File TM Jr, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/35\">",
"      Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/36\">",
"      Nelson ML, Levy SB. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 1999; 43:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/37\">",
"      Steigbigel NH, Reed CW, Finland M. Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro. Am J Med Sci 1968; 255:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/38\">",
"      SCHAEDLER RW, CHOPPIN PW, ZABRISKIE JB. PNEUMONIA CAUSED BY TETRACYCLINE-RESISTANTPNEUMOCOCCI. N Engl J Med 1964; 270:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/39\">",
"      Holt R, Evans TN, Newman RL. Tetracycline-resistant pneumococci. Lancet 1969; 2:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/40\">",
"      Kahlmeter G, Kamme C. Tetracycline-resistant group A streptococci and pneumococci. Scand J Infect Dis 1972; 4:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/41\">",
"      Tetracycline resistance in pneumococci and group A streptococci. Report of an ad-hoc study group on antibiotic resistance. Br Med J 1977; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     File, T, Craig, W, Farrell, DJ, Patterns of antibacterial susceptibility among Streptococcus pneumoniae isolates obtained from patients with community-acquired pneumonia: update from PROTEKT US year 5. 44th Annual Meeting of the Infectious Diseases Society of America, October 12-15, 2006. Abstract #253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/43\">",
"      Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/44\">",
"      Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995. Antimicrob Agents Chemother 2001; 45:1721.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, RN, Mera, RM, Miller, LA, et al. Pneumococcal conjugate vaccine (PCV7) effect on antibiograms: serotype and susceptibility rate changes in the SENTRY antimicrobial surveillance program (USA). 44th Annual Meeting of the Infectious Diseases Society of America, October 12-15, 2006. Abstract #476.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/46\">",
"      Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47:1867.",
"     </a>",
"    </li>",
"    <li>",
"     Musher D, unpublished.",
"    </li>",
"    <li>",
"     Kucers, A, Bennett, NM. The use of antibiotics: a comprehensive review with clinical emphasis. London: William Heinemann Medical Books Ltd, 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/49\">",
"      Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999; 159:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/50\">",
"      Punakivi L, Keistinen T, Backman R, et al. Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis. Scand J Infect Dis Suppl 1990; 68:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/51\">",
"      Hitchings GH. Mechanism of action of trimethoprim-sulfamethoxazole. I. J Infect Dis 1973; 128:Suppl:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/52\">",
"      Burchall, JJ. Mechanism of action of trimethoprim-sulfamethoxazole. II. J Infect Dis 1973; 128:Suppl:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/53\">",
"      Simberkoff MS, Lukaszewski M, Cross A, et al. Antibiotic-resistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York. J Infect Dis 1986; 153:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/54\">",
"      Henderson FW, Gilligan PH, Wait K, Goff DA. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. J Infect Dis 1988; 157:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/55\">",
"      Reeves, RR, Musher, DM. Antibiotic-resistant pneumococcus in a hemophiliac with AIDS. Hosp Pract 1991; 26:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/56\">",
"      Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/57\">",
"      Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/58\">",
"      Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb Drug Resist 2009; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/59\">",
"      Chodosh S, Eichel B, Ellis C, et al. Trimethoprim-sulfamethoxazole compared with ampicillin in acute infectious exacerbations of chronic bronchitis: a double-blind, crossover study. J Infect Dis 1973; 128:Suppl:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/60\">",
"      Quick CA, Wagner D. Trimethoprim-sulfamethoxazole in the treatment of infections of the ears, nose, and throat. J Infect Dis 1973; 128:Suppl:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/61\">",
"      Howie VM, Dillard R, Lawrence B. In vivo sensitivity test in otitis media: efficacy of antibiotics. Pediatrics 1985; 75:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3369/abstract/62\">",
"      Shurin PA, Pelton SI, Donner A, et al. Trimethoprim-sulfamethoxazole compared with ampicillin in the treatment of acute otitis media. J Pediatr 1980; 96:1081.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7028 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3369=[""].join("\n");
var outline_f3_18_3369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1720181033\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FLUOROQUINOLONES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms of action and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute exacerbation of chronic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DOXYCYCLINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Introduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanisms of action and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevalence of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TRIMETHOPRIM-SULFAMETHOXAZOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mechanisms of action and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Activity and prevalence of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lower respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Upper respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1720181033\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=related_link\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3370="Considerations prior to initiating antiretroviral therapy";
var content_f3_18_3370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Considerations prior to initiating antiretroviral therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3370/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3370/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3370/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/18/3370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/18/3370/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/18/3370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of the introduction of potent combination antiretroviral therapy (ART) in 1996, there was a \"hit hard and hit early\" approach to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/1\">",
"     1",
"    </a>",
"    ]. However, when the toxicities and resistance of chronic ART became apparent and complicated dosing regimens thwarted adherence, the pendulum swung back to withholding therapy in patients with relatively preserved CD4 cell counts.",
"   </p>",
"   <p>",
"    Advances in HIV therapy in the last decade have shifted the risk-benefit ratio to earlier treatment. HIV treatment guidelines from the United States Department of Health and Human Services (DHHS) and the International Antiviral Society-USA (IAS-USA) panels now recommend antiretroviral treatment in all patients with HIV infection, regardless of CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The strength of evidence supporting this recommendation varies by the pretreatment CD4 cell count.",
"   </p>",
"   <p>",
"    This topic will address issues related to the evaluation of the chronically infected HIV-seropositive patient prior to starting therapy and other specific considerations that may influence treatment decisions in the individual patient. Indications for initiating ART in the chronically infected HIV-infected patient, relative efficacy of different regimens, patient evaluation, and laboratory monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the initiation of HIV therapy in the patient with acute HIV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION PRIOR TO INITIATION OF ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient&rsquo;s readiness to adhere to lifelong chronic therapy must also be assessed prior to treatment initiation, although the urgency to start antiretroviral therapy (ART) is greater in patients with advanced immunocompromise. Certain patient considerations and comorbidities will also affect selection of specific antiretroviral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history should include evaluation of the patient's HIV status (eg, HIV RNA, CD4 cell count), other comorbidities, family history, likelihood of adherence, and general knowledge of HIV infection. Historical information that may be helpful in selecting antiretroviral medications includes history of renal disease, chronic viral hepatitis, and plans for pregnancy among female patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient's current health status should be reviewed, with particular attention to recent hospitalizations or evidence of chronic illness that may reflect advanced immunocompromise, such as unexplained fevers, weight loss, fatigue, chronic diarrhea, visual symptoms, or cognitive dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initiation of ART can lead to a microbe-specific inflammatory response called the &ldquo;immune reconstitution inflammatory syndrome&rdquo;, or IRIS, among those with undiagnosed opportunistic infections. Thus, a complete review of systems should be performed, particularly in the patient with advanced AIDS, to assess any potential underlying infection, such as pulmonary tuberculosis or cryptococcal meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H20#H20\">",
"       \"Immune reconstitution inflammatory syndrome\", section on 'Timing of antiretroviral therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is important to ascertain whether the patient has any other comorbidities that may be relevant in the selection of antiretroviral medications. For example, antiretroviral medications with dual activity against HIV and hepatitis B are preferred in the HIV-infected patient with chronic hepatitis B infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link&amp;anchor=H913317#H913317\">",
"       \"Treatment of hepatitis B in the HIV-infected patient\", section on 'Treatment recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinician should also evaluate the patient for a history of other comorbidities that may influence drug selection such as dyslipidemia, diabetes, and coronary artery disease, since some ART regimens have fewer metabolic effects than others. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link&amp;anchor=H20#H20\">",
"       \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\", section on 'Choice of initial drug regimen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Female patients should be assessed regarding their reproductive and pregnancy status. Medication selection will be more restricted if the patient could become pregnant, since the nonnucleoside reverse transcriptase inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , is not recommended during the first trimester. The treatment of the pregnant HIV-infected woman is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Knowledge of all concomitant medications is essential to determine the possibility of drug interactions. This includes over the counter drugs and herbal medications. Drug-drug interactions are of particular concern among patients who are considering hepatitis C virus treatment for genotype 1 infection with a hepatitis C virus protease inhibitor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=see_link\">",
"       \"Monitoring the HIV-infected patient taking hepatitis C therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link&amp;anchor=H819606#H819606\">",
"       \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'Potential drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A thorough drug allergy history should be obtained; those with a history of sulfa allergy may have hypersensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      , which contains a sulfa moiety. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link&amp;anchor=H29#H29\">",
"       \"HIV protease inhibitors\", section on 'Darunavir (prezista)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Knowledge of whether there is discordance between a patient and sexual partner in terms of HIV serostatus is also helpful for couples counseling since HIV treatment of the infected patient can decrease the risk of HIV transmission to the uninfected partner. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link&amp;anchor=H12048649#H12048649\">",
"       \"HIV treatment as prevention\", section on 'Clinical management of HIV serodiscordant couples'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Psychosocial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful psychosocial history is important since psychosocial factors can have a strong influence on patient adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/4\">",
"     4",
"    </a>",
"    ]. Prior adherence to pill taking for other medical conditions can be helpful in determining \"treatment readiness\".",
"   </p>",
"   <p>",
"    Issues to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors that contribute to chaotic or unstable lives such as injection drug use, alcoholism, and homelessness [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/5\">",
"       5",
"      </a>",
"      ]. None of these should negate the opportunity to receive ART, but they require special efforts and resources. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2551?source=see_link\">",
"       \"Substance abuse and addiction in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychiatric disorders (eg, anxiety, depression, bipolar disorder) may interfere with a patient's ability or desire to adhere to a medication regimen. Also, certain medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , should be used with caution in the presence of a major mental illness because of its central nervous system toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12504?source=see_link\">",
"       \"Depression, mania, and schizophrenia in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with irregular work schedules may have difficulty taking medications at prescribed times.",
"     </li>",
"     <li>",
"      Affordability of medications may be a major constraint for some patients depending on the state or country where they live, their economic resources, and their medical insurance. Certain medications are now available as generic drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A patient&rsquo;s specific employment situation may influence ART drug selection. For example, some medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ) can cause dizziness or have cognitive side effects, which can interfere with job performance or safety. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"       \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two points worthy of emphasis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physicians have been notoriously inaccurate in predicting which patients will be adherent to medical regimens.",
"     </li>",
"     <li>",
"      Patients should not be denied access to ART based solely on history of psychiatric illness or disordered lifestyle. The challenge is to maximize adherence in all patients and to select drugs based to some extent on adherence demands and individual preference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical exam should be thorough, but will be restricted here to issues relevant to HIV and the initiation of ART.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight and height, for calculation of body mass index (BMI): It is important to obtain a baseline assessment of BMI and general habitus since certain antiretroviral medications can affect fat distribution over time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fundoscopic exam: The patient with a history of visual floaters may need referral for a dilated fundoscopic examination by an ophthalmologist to evaluate for cytomegalovirus (CMV)-related retinitis, particularly if the CD4 count is &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      Soon after starting ART, patients with underlying CMV retinitis may develop immune recovery vitreitis, characterized by a decline in visual function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral cavity: Inspect for thrush, oral hairy leukoplakia, and Kaposi's sarcoma, since these suggest advanced HIV infection and urgent need for ART and prophylaxis for opportunistic infections.",
"     </li>",
"     <li>",
"      Skin: Inspect for rashes (eg, Kaposi sarcoma, seborrheic dermatitis, folliculitis and herpes simplex). In patients with Kaposi sarcoma, ART is associated with regression in the size of existing lesions and possibly improved survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal exam: Hepatomegaly or splenomegaly may suggest advanced liver disease due to alcoholism or chronic viral hepatitis, which is a risk factor for drug-induced liver injury; alternatively, hepatosplenomegaly may be due to infiltrative disease, such as malignancy or Bartonellosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link&amp;anchor=H32#H32\">",
"       \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\", section on 'HCV and risk of hepatotoxicity with ART'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genital exam: This should include pelvic exam and perianal inspection for evidence of human papillomavirus (HPV) infection or other sexually transmitted diseases. Anal intraepithelial neoplasia and anal cancer secondary to HPV infection are increasing in incidence among HIV-infected men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. It is yet unclear if ART will ameliorate HPV-related disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"       \"HIV and women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"       \"Approach to the patient with genital ulcers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurologic exam: This should include evaluation of mental status, cognition, concentration, coordination, and memory; neurologic abnormalities may suggest HIV-associated dementia. Patients with possible HIV-associated dementia (HAD) should have formal testing for staging such as the \"HIV dementia scale\" [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/10\">",
"       10",
"      </a>",
"      ]. For those with HAD, ART increases longevity and may slow disease progression, but it is not clear that it reverses previous losses [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=see_link\">",
"       \"Dementia and delirium in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9550610\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to be fully educated about HIV since it is a lifelong infection with outcome largely dependent on the quality of self-care. Specific issues to discuss include natural history of HIV infection, the extraordinary benefits of ART, issues of confidentiality and disclosure, and mechanisms of transmission. The patient must have a clear understanding of the role of sex and injection drug use in HIV transmission, the importance of disclosure to those who have been placed at risk, and methods to reduce risk, including HIV treatment as prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9550589\">",
"    <span class=\"h2\">",
"     General laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients being considered for antiretroviral therapy (ART) should have the following laboratory tests to evaluate their HIV status and to determine if there are comorbidities that may influence selection of antiretroviral medications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CD4 count is a major determinant of the severity of the underlying immunocompromise. A CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      is diagnostic for AIDS. Additional caveats about the interpretation of CD4 counts and HIV RNA levels are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"       \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"       \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The selection of certain antiretroviral medications is influenced by the height of the pretreatment viral load. For example, certain HIV treatment guidelines recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      as the nucleoside analog backbone for combination ART rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"       abacavir-lamivudine",
"      </a>",
"      in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2,14\">",
"       2,14",
"      </a>",
"      ]. Serial monitoring of the HIV viral load also helps to determine the effectiveness of ART. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H29#H29\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Nucleoside analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete blood count with differential: Antiretroviral medications associated with bone marrow suppression, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      , should be avoided in patients with evidence of leukopenia and anemia; zidovudine is no longer recommended as first-line therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"       \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolytes, BUN, creatinine, and urinalysis: Evidence of baseline renal insufficiency (eg, creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      should deter use of antiretroviral medications that are associated with elevations in creatinine, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . Information about medication dose adjustments in patients with a creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      are found in the respective drug information topics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link&amp;anchor=H11211178#H11211178\">",
"       \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Use in patients with renal or hepatic insufficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fasting glucose and lipid profile: Elevations of fasting glucose, triglycerides, or cholesterol may be exacerbated by administration of certain antiretroviral medications. Treatment considerations are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"       \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"       \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"       \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H20\">",
"       'Cardiovascular disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Liver function tests and serologic testing for hepatitis B and C viruses: Patients with chronic viral hepatitis and elevations of aminotransferases have an increased risk of drug-associated hepatotoxicity. Serologic testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis C (anti-HCV) should be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link\">",
"       \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"       \"Patient monitoring during HIV antiretroviral therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , genetic testing for HLA-B*5701 should be obtained prior to its administration, since a positive result predicts risk of abacavir hypersensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"       \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"       \"Abacavir hypersensitivity reaction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chest x-ray is considered optional, but should be obtained in any patient with pulmonary symptoms or a positive test for latent tuberculosis. Other general screening laboratory tests in HIV-infected patients are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16712?source=see_link\">",
"       \"Screening laboratory tests in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HIV resistance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine resistance testing is recommended prior to initiation of ART in all patients with an HIV RNA level &gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Baseline resistance testing is done on the first visit to detect transmitted HIV drug resistance. The earlier this test is obtained after viral transmission, the more likely it is to detect transmitted resistance, which can affect the effectiveness of ART. Knowledge of current and any past HIV drug resistance patterns is critical so the patient is not exposed to a partially suppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1111798\">",
"    <span class=\"h2\">",
"     HIV tropism assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCR5 antagonists exert their anti-HIV activity by blocking entry of CCR5-tropic viruses into the CD4 cell. HIV enters CD4+ cells via the CD4 receptor in conjunction with one of its coreceptors: the chemokine coreceptor 5 (CCR5) or the CXC chemokine coreceptor 4 (CXCR4) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/17\">",
"     17",
"    </a>",
"    ]. Viruses that use the CCR5 coreceptor are called \"R5 viruses\", whereas others that use the CXCR4 coreceptor are called \"X4 viruses\".",
"   </p>",
"   <p>",
"    A phenotypic tropism assay is recommended by major consensus committees prior to initiation of therapy with CCR5 antagonists, because these drugs are not active against X4 or dual-mixed tropic viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. The tropism assay is similar to an HIV resistance phenotype and can determine whether a response from a CCR5 antagonist should be expected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\", section on 'Tropism assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Screening for tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of tuberculosis is increased 100-fold in persons with HIV infection and the enhanced risk applies to all CD4 strata [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/19\">",
"     19",
"    </a>",
"    ]. The sensitivity of purified protein derivative (PPD) skin tests is reduced with HIV-associated immunocompromise. The interferon-gamma (NF-8) release assay is more expensive than a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    , but has advantages of increased specificity, elimination of the need for patients to return for interpretation, and possibly increased sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/20\">",
"     20",
"    </a>",
"    ]. Recommendations for prophylaxis of latent tuberculosis are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link&amp;anchor=H6037122#H6037122\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\", section on 'Management strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic testing for risk of abacavir hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA-B*5701 has been demonstrated to be a predictor of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity; this test should be performed prior to abacavir exposure, whenever feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEDICATION CONSIDERATIONS WHEN CHOOSING ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although efficacy of an antiretroviral regimen is a primary consideration, aspects of a regimen that affect adherence, including pill burden, dosing frequency, and side effects, are also important to the eventual success or failure of the regimen. Additionally, since patients may require antiretroviral therapy (ART) for years or decades, potential long-term side effects of regimens should be considered (",
"    <a class=\"graphic graphic_table graphicRef86498 \" href=\"UTD.htm?16/14/16623\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The selection of ART considers potency, convenience, tolerance, and toxicity. Some of these considerations are discussed below. Guideline recommendations regarding combinations of drug classes from the International Antiviral Society-USA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2\">",
"     2",
"    </a>",
"    ] and United States Department of Health and Human Services (",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/\">",
"     file://AIDSinfo.nih.gov",
"    </a>",
"    ) are discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Constructing a regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since HIV infection is characterized by high rates of replication by a virus with an error-prone reverse transcriptase enzyme, combination therapy is required for prolonged viral suppression. For more than a decade, the optimal approach to treatment has been with the use of three antiretroviral medications, which often include two nucleoside reverse transcriptase inhibitors (NRTIs) as the \"backbone\" of therapy with either a \"boosted\" protease inhibitor (PI) a nonnucleoside reverse transcriptase inhibitor (NNRTI) or an integrase strand transfer inhibitor (ISTI).",
"   </p>",
"   <p>",
"    Choice of antiretroviral therapy regimens is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2648304\">",
"    <span class=\"h2\">",
"     Dosing frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens that require fewer doses per day improve adherence. For example, in a retrospective study of 1917 patents initiating ART between 2000 and 2007, increased regimen durability was found to be directly related to lower dosing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First-line antiretroviral agents that are approved by the US Food and Drug Administration (FDA) for once-daily administration include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NRTIs:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (300 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      (600 mg)",
"     </li>",
"     <li>",
"      NNRTIs:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (600 mg)",
"     </li>",
"     <li>",
"      PIs:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      -ritonavir",
"      <span class=\"nowrap\">",
"       (300/100",
"      </span>",
"      mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -ritonavir",
"      <span class=\"nowrap\">",
"       (800/100",
"      </span>",
"      mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some important alternative NNRTI agents that can be given once daily include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    (400 mg XL) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    (25 mg).",
"   </p>",
"   <p>",
"    Another issue that can impact adherence is restrictions on dosing; for example, certain medications must be taken either with food (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ) or on an empty stomach (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ), whereas there are no food restrictions with some other medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pill burden and coformulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier ART regimens, particularly those that included PIs, frequently required patients to ingest many large pills with each dose. Newer drugs, regimens, and pill formulations have reduced this burden dramatically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NRTI pairings that are available as a single pill include:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (TDF) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (FTC), coformulated as Truvada, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      (ABC) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (3TC), coformulated as Epzicom. Both coformulations are taken once daily.",
"      <br/>",
"      <br/>",
"      Truvada is the only first-line coformulation that combines two agents with dual",
"      <span class=\"nowrap\">",
"       HIV/hepatitis",
"      </span>",
"      B virus activity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The three-drug combination, Atripla, combines",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (600 mg) into a single pill taken once daily [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/22\">",
"       22",
"      </a>",
"      ]. This coformulation is bioequivalent to administration of its individual components [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other coformulations are available, which combine a two-class, three-drug combination ART regimen within one pill: Complera includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      (25 mg daily), and the Quad pill (Stribild) includes tenofovir, emtricitabine, elvitegravir (150 mg), and cobicistat (150 mg), a pharmacokinetic enhancer.",
"     </li>",
"     <li>",
"      Among the first-line PIs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      (Reyataz) can be taken as two capsules once a day in the treatment-naive and treatment-experienced patient.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      -ritonavir (Prezista) is approved for once-daily dosing (four tablets) in treatment-naive patients in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"       \"HIV protease inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should also check for any potential drug interactions with the medications the patient is already taking. For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    has significant drug interactions with most protease inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential drug-drug interactions are important considerations in the patient who is a treatment candidate for hepatitis C virus genotype 1 infection. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Chronic viral hepatitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATIENT CONSIDERATIONS WHEN CHOOSING ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When making treatment decisions about which medications to prescribe, adverse profiles of each drug need to be considered in the context of the individual patient, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Methadone recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug interactions are an important consideration in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance. The nonnucleoside reverse transcriptase inhibitors (NNRTIs)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    can cause significant reductions in methadone levels, which may result in opiate withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/25\">",
"     25",
"    </a>",
"    ]. The patient must be carefully monitored for withdrawal symptoms with appropriate dose adjustment of methadone. Protease inhibitors (PIs) reduce methadone levels, but to a lesser extent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ethanol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    is metabolized primarily by alcohol dehydrogenase; serum levels of abacavir increased by more than 40 percent in 24 HIV-infected patients who were given abacavir and the equivalent of five alcoholic drinks daily [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/26\">",
"     26",
"    </a>",
"    ]. For this reason, abacavir is not recommended for use in patients with heavy ethanol use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic viral hepatitis are at increased risk for drug-associated hepatotoxicity. Prior to initiating antiretroviral therapy (ART), patients should be counseled about symptoms of drug-associated hepatotoxicity, such as right upper quadrant pain, nausea, vomiting, fatigue, loss of appetite, and jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients must be instructed to contact their provider should these symptoms occur.",
"   </p>",
"   <p>",
"    In the patient with chronic hepatitis B virus (HBV), choice of nucleoside reverse transcriptase inhibitor (NRTI) should also take into account those medications that have dual activity against HIV and HBV (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ART regimens must be carefully selected for HIV-infected patients with Hepatitis C virus (HCV) genotype 1 infection who are treatment candidates for HCV protease inhibitor therapy since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    have several potential drug-drug interactions with certain antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among some HIV-infected treatment-naive patients who have CD4 counts &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    HCV therapy may be initiated prior to ART to avoid such drug interactions. The management of the",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patient is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link&amp;anchor=H819606#H819606\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'Potential drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with known cardiovascular disease (CVD) or at high risk for CVD, it is prudent to choose medications that have a less adverse effect on the lipid profile. In the NNRTI category, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    would be favored. In the PI class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    has a more favorable lipid profile than many other PIs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    , an integrase inhibitor, also has a favorable lipid profile [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Risk of myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When assessing the risk of myocardial infarction, clinicians should focus mainly on traditional risk factors for coronary artery disease, such as smoking or family history of myocardial infarction. There are conflicting data as to whether there is an increased risk of myocardial infarction related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In treatment-naive patients at high risk for coronary artery disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    may be preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    as the nucleoside analog backbone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link&amp;anchor=H27#H27\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Cardiovascular disease associated with HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is generally well tolerated, but should generally not be used in patients with a creatinine &lt;50",
"    <span class=\"nowrap\">",
"     cc/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]. Among patients without pre-existing renal disease, tenofovir appears to be relatively safe, including in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic meta-analysis of 17 studies demonstrated a statistically significant loss of renal function associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , although the clinical magnitude of the effect was modest [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/36\">",
"     36",
"    </a>",
"    ]. Other data suggest that there may be a greater initial decline in glomerular filtration rates when tenofovir is coadministered with PIs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ) compared with NNRTIs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]; however, this decline appears to stabilize after six months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/37\">",
"     37",
"    </a>",
"    ]. The pharmacokinetic enhancer cobicistat, which is incorporated in Stribild (also known as Quad) can affect estimates of glomerular function through its inhibition of creatinine secretion in the proximal tubule. In clinical trials, the use of Stribild was also associated with renal tubular dysfunction with onset of proteinuria in approximately 0.6 percent of patients. &nbsp;",
"   </p>",
"   <p>",
"    Other ART drugs are not nephrotoxic, but some require dose modification with impaired renal function. Administration of coformulations is not recommended in patients with renal insufficiency. Dose modification is required in patients requiring dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9549975\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the increased risk of fragility fractures in postmenopausal women,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    is generally preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    because of the accelerated bone loss seen in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link&amp;anchor=H8#H8\">",
"     \"Bone and calcium disorders in HIV-infected patients\", section on 'Tenofovir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Immune status",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    -based ART should not be the initial regimen in a female patient with a CD4 count &gt;250",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and in a male patient with a CD4 count &gt;400",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    because of an increased risk of hepatotoxicity and rash. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9550089\">",
"    <span class=\"h2\">",
"     Baseline level of viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a large clinical trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    in combination with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    for initial HIV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/39\">",
"     39",
"    </a>",
"    ]. At a median of 60 weeks of follow-up,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was associated with a significant increased risk of virologic failure among patients with a pretreatment viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, conflicting results were demonstrated in a non-inferiority trial where the same NRTI-paired combinations were associated with similar rates of viral suppression among patients with high-level baseline viremia when paired with a different third agent (ie, lopinavir) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HIV treatment guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    as the preferred NRTI backbone combination for patients with high baseline levels of viremia &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    , an NNRTI, is not recommended for patients with high level viremia (&gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL);",
"    </span>",
"    in this particular scenario,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is the preferred NNRTI agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Patients with tuberculosis infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of HIV therapy in the patient with active tuberculosis is complex and needs to be approached with caution because of risks of drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and the immune reconstitution syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/18/3370/abstract/42\">",
"     42",
"    </a>",
"    ]. The timing of ART relative to the treatment of tuberculosis and other issues of concern are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patients with depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians prefer to avoid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in patients with significant depressive symptoms, since this agent has central nervous system side effects, including headache and mood instability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"       \"Patient information: Starting treatment for HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The medical history should include evaluation of the patient's HIV status, comorbidities, likelihood of adherence, and general knowledge of HIV infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient evaluation prior to initiation of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's current health status should be reviewed, with particular attention to recent hospitalizations or evidence of chronic illness that may reflect advanced immunocompromise, such as unexplained fevers, weight loss, fatigue, chronic diarrhea, visual symptoms, or cognitive dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient evaluation prior to initiation of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Baseline laboratory tests that are critical to evaluate urgency to treat and facilitate drug selection include a CD4 T-cell count, HIV RNA level, and HIV genotypic drug resistance testing.",
"     </li>",
"     <li>",
"      General laboratory testing for evidence of other comorbidities that may influence drug selection include: serum creatinine, hepatitis B surface antigen, aminotransferases and prothrombin time, fasting lipid profile and fasting blood glucose, and presence of HLA-B*5701 (if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      is to be used). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal management of HIV infection also requires evaluation of HIV viral load, drug resistance testing, and a tropism assay if a CCR5 antagonist is being considered as part of the combination regimen. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choice of a particular regimen should take into consideration pill burden, dosing frequency, food requirements, potential drug interactions, tolerance, and HIV drug resistance. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medication considerations when choosing antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient considerations in choosing antiretroviral therapy (ART) also include substance abuse,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      treatment, and cardiovascular disease or risk. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patient considerations when choosing antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the risk of teratogenicity,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      should be avoided during the first trimester of pregnancy or in a woman who may become pregnant. When efavirenz is administered to a woman of childbearing potential, counseling on adequate contraception must be advised. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patient considerations when choosing antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with",
"      <span class=\"nowrap\">",
"       HIV/hepatitis",
"      </span>",
"      B virus coinfection, the nucleoside analog backbone should include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Chronic viral hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      is generally well tolerated, but should generally not be used in patients with a creatinine &lt;50",
"      <span class=\"nowrap\">",
"       cc/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      should not be used with a baseline BL &gt;100,000",
"      <span class=\"nowrap\">",
"       c/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H9550089\">",
"       'Baseline level of viremia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/1\">",
"      Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/2\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/4\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/5\">",
"      Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004; 39:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/6\">",
"      de Pokomandy A, Rouleau D, Ghattas G, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011; 52:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/7\">",
"      Hessol NA, Holly EA, Efird JT, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/8\">",
"      Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009; 4:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/9\">",
"      van der Snoek EM, van der Ende ME, den Hollander JC, et al. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis 2012; 39:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/10\">",
"      Davis HF, Skolasky RL Jr, Selnes OA, et al. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/11\">",
"      Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/12\">",
"      Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/13\">",
"      Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009; 48:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/14\">",
"      Chui CK, Brumme ZL, Brumme CJ, et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007; 44:1503.",
"     </a>",
"    </li>",
"    <li>",
"     DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents December 1, 2009. www.AIDSinfo.nih.gov (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/16\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/17\">",
"      Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/18\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/19\">",
"      Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/20\">",
"      Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/21\">",
"      Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/22\">",
"      Atripla approval a model for collaborative development of combos, FDA says. In: \"The Pink Sheet\" 2006; 68:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/23\">",
"      Mathias AA, Hinkle J, Menning M, et al. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007; 46:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/24\">",
"      Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/25\">",
"      Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006; 368:1503.",
"     </a>",
"    </li>",
"    <li>",
"     Ziagen (abacavir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline Inc.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/27\">",
"      Soriano V, Puoti M, Garcia-Gasc&oacute; P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/28\">",
"      Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/29\">",
"      D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.",
"     </a>",
"    </li>",
"    <li>",
"     Lundgren J, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. XVII International AIDS Conference, Mexico City, August 3-8, 2008. Abstract #THAB0305.",
"    </li>",
"    <li>",
"     Cutrell A, Hernandez J, Yeo J, et al. Is abacavir-containing combination antiretroviral therapy associated with myocardial infarction? No association identified in pooled summary of 54 clinical trials. XVII International AIDS Conference, Mexico City, August 3-8, 2008. Abstract # THAB0305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/32\">",
"      Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on July 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/34\">",
"      Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008; 22:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/35\">",
"      Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009; 23:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/36\">",
"      Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/37\">",
"      Young J, Sch&auml;fer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/38\">",
"      Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/39\">",
"      Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/40\">",
"      Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/41\">",
"      Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/18/3370/abstract/42\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3790 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3370=[""].join("\n");
var outline_f3_18_3370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT EVALUATION PRIOR TO INITIATION OF ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Psychosocial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9550610\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9550589\">",
"      General laboratories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HIV resistance testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1111798\">",
"      HIV tropism assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Screening for tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic testing for risk of abacavir hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEDICATION CONSIDERATIONS WHEN CHOOSING ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Constructing a regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2648304\">",
"      Dosing frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pill burden and coformulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATIENT CONSIDERATIONS WHEN CHOOSING ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Methadone recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ethanol abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Risk of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9549975\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Immune status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9550089\">",
"      Baseline level of viremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Patients with tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patients with depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/14/16623\" title=\"table 1\">",
"      Advantages and disadvantages of initial ART",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=related_link\">",
"      Dementia and delirium in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12504?source=related_link\">",
"      Depression, mania, and schizophrenia in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=related_link\">",
"      Monitoring the HIV-infected patient taking hepatitis C therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16712?source=related_link\">",
"      Screening laboratory tests in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2551?source=related_link\">",
"      Substance abuse and addiction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_18_3371="Neonatal ETT size";
var content_f3_18_3371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endotracheal tube sizes for neonatal resuscitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tube size, mm, inside diameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight, grams",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        &lt;28",
"       </td>",
"       <td>",
"        &lt;1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        28-34",
"       </td>",
"       <td>",
"        1000-2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        34-38",
"       </td>",
"       <td>",
"        2000-3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.5-4.0",
"       </td>",
"       <td>",
"        &gt;38",
"       </td>",
"       <td>",
"        &gt;3000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Use No. 0 laryngoscope blade for preterm infants, and No. 1 for term infants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3371=[""].join("\n");
var outline_f3_18_3371=null;
var title_f3_18_3372="Potential uses of SAECG";
var content_f3_18_3372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential uses of the signal averaged electrocardiogram",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stratification of risk for ventricular arrhythmias and cardiac and sudden death mortality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmogenic right ventricular dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Use for diagnosis and treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assessment of efficacy of antiarrhythmic medications or arrhythmia surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noninvasive diagnosis of cardiac transplant rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequently recurrent paroxysmal atrial fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measurement of His bundle electrograms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other disorders in which the SAECG is abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duchenne muscular dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myotonic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive systemic sclerosis (scleroderma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anthracycline cardiotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Following surgical repair of congenital heart disease, especially tetralogy of Fallot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chagas' heart disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3372=[""].join("\n");
var outline_f3_18_3372=null;
var title_f3_18_3373="Human TCR alpha chain";
var content_f3_18_3373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Organization of the human T cell receptor alpha chain locus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 96px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are 49 V alpha genes of which seven are pseudogenes in some haplotypes. Five of these V alpha genes may also recombine with gene segments in the delta chain&nbsp;locus. One V delta gene is also in the V alpha region. There are 61 J alpha gene segments of which three are pseudogenes, and eight are not utilized, although they contain open reading frames (ORFs). There is a single C alpha gene.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Leiden, JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3373=[""].join("\n");
var outline_f3_18_3373=null;
var title_f3_18_3374="Polyp on virtual colonoscopy";
var content_f3_18_3374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 194px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Virtual colonoscopy shows a small polyp (arrow) in the transverse colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3374=[""].join("\n");
var outline_f3_18_3374=null;
var title_f3_18_3375="Cytology pancreatic cancer";
var content_f3_18_3375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fine needle aspirate of pancreatic cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cluster of malignant cells is seen in this aspirate taken from a patient with a pancreatic mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael L Steer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_18_3375=[""].join("\n");
var outline_f3_18_3375=null;
